var title_f14_26_14752="Abdominal endograft limb thrombosis";
var content_f14_26_14752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abdominal endograft limb thrombosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 251px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The contrast angiogram shows absence of filling of the left limb of bifurcated endograft due to thrombosis (red arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14752=[""].join("\n");
var outline_f14_26_14752=null;
var title_f14_26_14753="Impaired aqueous flow";
var content_f14_26_14753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Impaired aqueous flow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Aqueous fluid normally flows through the trabecular meshwork into Schlemm's canal, from which it drains into the venous system. When the drainage of aqueous fluid from the anterior chamber is compromised, as depicted here, intraocular pressure increases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Trobe JD. The Physician's Guide to Eye Care. Foundation of the American Academy of Ophthalmology, San Francisco, 2001. p.158. Copyright &copy; American Academy of Ophthalmology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14753=[""].join("\n");
var outline_f14_26_14753=null;
var title_f14_26_14754="Oropharyn airway insert";
var content_f14_26_14754=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Oropharyngeal airway insertion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When inserting an OPA, the clinician must avoid pushing the tongue into the posterior pharynx. This can be accomplished by starting with the curve of the OPA inverted (ie, directed cephalad) and then rotating it 180 degrees as its tip reaches the posterior pharynx.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14754=[""].join("\n");
var outline_f14_26_14754=null;
var title_f14_26_14755="Carcinoid heart disease";
var content_f14_26_14755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carcinoid heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 559px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Pulmonary valve (autopsy specimen, viewed from above). Diffuse carcinoid plaques have caused thickening and retraction of all three cusps and appreciable constriction of the annulus (valve ring). The result is a small fixed triangular orifice that was both stenotic and regurgitant clinically. B) Normal pulmonary valve, for comparison with (A) (autopsy specimen, viewed from above). All three cusps are thin and coapt (come together) centrally, and the annulus (valve ring) is neither constricted or dilated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. William D. Edwards, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14755=[""].join("\n");
var outline_f14_26_14755=null;
var title_f14_26_14756="Cyclosporine (ophthalmic): Drug information";
var content_f14_26_14756=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyclosporine (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/52/6980?source=see_link\">",
"    see \"Cyclosporine (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/42/23202?source=see_link\">",
"    see \"Cyclosporine (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8012533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Restasis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14959798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Restasis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8105271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Immunosuppressant Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8012638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Keratoconjunctivitis sicca:",
"     </b>",
"     Ophthalmic: Instill 1 drop in each eye every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8105272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/42/23202?source=see_link\">",
"      see \"Cyclosporine (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Keratoconjunctivitis sicca:",
"     </b>",
"     Ophthalmic: Adolescents &ge;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8012639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16053036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16053037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8012680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Emulsion, ophthalmic [drops, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Restasis&reg;: 0.05% (0.4 mL) [contains castor oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8012548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8012664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Prior to use, invert vial several times to obtain a uniform emulsion. Remove contact lenses prior to instillation of drops; may be reinserted 15 minutes after administration. May be used with artificial tears; allow 15 minute interval between products. To avoid contamination, do not touch vial tip to eyelids or other surfaces.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8012549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Increase tear production when suppressed tear production is presumed to be due to keratoconjunctivitis sicca-associated ocular inflammation (in patients not already using topical anti-inflammatory drugs or punctal plugs)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8012532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       CycloSPORINE may be confused with cyclophosphamide, Cyklokapron&reg;, cycloSERINE",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8012585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Ocular: Burning (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 5%: Ocular: Blurred vision, conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Eye injury, hypersensitivity reactions (including eye swelling, urticaria, severe angioedema (rare), face swelling, tongue swelling, pharyngeal edema, and dyspnea)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8012551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyclosporine or any component of the formulation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8012562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Remove contact lens prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: To avoid contamination, do not touch vial tip to eyelids or other surfaces.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8012590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8029321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10923624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed following the use of oral cyclosporine in animal reproduction studies when using doses that were approximately 300,000 times greater than a human ophthalmic dose (assuming complete absorption).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8029327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10923625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cyclosporine is found in breast milk following oral administration. Serum concentrations are below the limit of detection (&lt;0.1 ng/mL) following ophthalmic use.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8012682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Restasis Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (1): $5.67",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cyclomune (IN);",
"     </li>",
"     <li>",
"      Modusik-A Ofteno (CN, CR, DO, GT, HN, NI, PA, PE, SV);",
"     </li>",
"     <li>",
"      Restasis (AR, BR, CN, CO, GR, HK, IL, KP, MY, PE, PH, TH, TW, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8012626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Absorption: Serum concentrations not detectable.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/26/14756/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9093 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14756=[""].join("\n");
var outline_f14_26_14756=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012533\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14959798\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8105271\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012638\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8105272\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012639\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16053036\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16053037\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012680\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012548\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012664\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012549\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012532\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012585\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012551\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012562\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299110\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012590\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8029321\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10923624\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8029327\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10923625\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012682\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961967\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012626\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9093\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9093|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/52/6980?source=related_link\">",
"      Cyclosporine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/42/23202?source=related_link\">",
"      Cyclosporine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/8/30858?source=related_link\">",
"      Cyclosporine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/28/40390?source=related_link\">",
"      Cyclosporine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/55/36729?source=related_link\">",
"      Cyclosporine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_26_14757="Primaquine: Pediatric drug information";
var content_f14_26_14757=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Primaquine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"    see \"Primaquine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/37/30292?source=see_link\">",
"    see \"Primaquine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimalarial Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"      see \"Primaquine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     The CDC recommends screening for G-6-PD deficiency prior to initiating treatment with primaquine. Dosage expressed as mg of",
"     <b>",
"      base",
"     </b>",
"     (15 mg base = 26.3 mg primaquine phosphate):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relapse prevention of",
"     <i>",
"      P. vivax",
"     </i>",
"     malaria: Uncomplicated malaria (",
"     <i>",
"      P. vivax",
"     </i>",
"     and",
"     <i>",
"      P. ovale",
"     </i>",
"     ): 0.5 mg base/kg once daily for 14 days (maximum dose: 30 mg base/day) (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of malaria (primarily",
"     <i>",
"      P. vivax",
"     </i>",
"     ): 0.5 mg base/kg once daily (maximum: 30 mg base/day); initiate  1-2 days prior to travel and continue for 7 days after departure from malaria-endemic area (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     (PCP) pneumonia treatment: 0.3 mg base/kg once daily (maximum: 30 mg base/day) for 21 days (in combination with clindamycin) (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relapse prevention of",
"     <i>",
"      P. vivax",
"     </i>",
"     malaria, uncomplicated malaria (",
"     <i>",
"      P. vivax",
"     </i>",
"     or",
"     <i>",
"      P. ovale",
"     </i>",
"     ): 30 mg base once daily for 14 days; alternative regimen (recommended for mild G-6-PD deficiency): 45 mg base once weekly for 8 weeks (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of chloroquine-resistant malaria: 30 mg base once daily, begin 1-2 days prior to travel and continue for 7 days after departure from malaria-endemic area",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     (PCP) pneumonia treatment: 30 mg base once daily for 21 days (in combination with clindamycin)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as phosphate: 26.3 mg [15 mg base]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with meals to decrease adverse GI effects; drug has a bitter taste",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For the radical cure (prevention of relapse) of vivax malaria (",
"     <i>",
"      P. vivax",
"     </i>",
"     ) [FDA approved in adults]; has also been used for prevention relapse of",
"     <i>",
"      P. ovale",
"     </i>",
"     , malaria postexposure prophylaxis, and treatment of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     (PCP) pneumonia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6704513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Primaquine may be confused with primidone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F213270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, hemolytic anemia (in patients with G6PD deficiency), leukopenia, leukocytosis, methemoglobinemia (in NADH-methemoglobin reductase-deficient individuals)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Interference with visual accommodation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acutely ill patients who have a tendency to develop granulocytopenia (rheumatoid arthritis, SLE); patients concurrently receiving drugs capable of depressing the bone marrow or receiving other drugs which can cause hemolytic anemia; patients receiving quinacrine",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with G-6-PD deficiency or NADH methemoglobin reductase deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6007553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemolytic reactions may occur in patients with G-6-PD deficiency and in individuals with a history of favism. Anemia, methemoglobinemia, and leukopenia have been associated with primaquine use; promptly discontinue with signs of hemolytic anemia (darkening of urine, marked fall in hemoglobin or erythrocyte count). CDC recommends that primaquine not be used during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F213260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong), CYP2D6 (weak), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anthelmintics: Aminoquinolines (Antimalarial) may decrease the serum concentration of Anthelmintics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Aminoquinolines (Antimalarial) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoquinolines (Antimalarial) may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: Aminoquinolines (Antimalarial) may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of Aminoquinolines (Antimalarial).  Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of an aminoquinoline antimalarial when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13801098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Primaquine use is not recommended in pregnant women per CDC Guidelines. Consult current CDC guidelines for the treatment of malaria during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic CBC, visual color check of urine, hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Eliminates the primary tissue exoerythrocytic forms of",
"     <i>",
"      P. falciparum",
"     </i>",
"     ,",
"     <i>",
"      P. malariae",
"     </i>",
"     ,",
"     <i>",
"      P. ovale",
"     </i>",
"     , and",
"     <i>",
"      P. vivax",
"     </i>",
"     ; interferes with plasmodial DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Liver metabolism to carboxyprimaquine, an active metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 3.7-9.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Small amount of unchanged drug excreted in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/37/30292?source=see_link\">",
"      see \"Primaquine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if a darkening of the urine occurs. Travelers must be tested for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency and have a documented G-6-PD in the normal range before initiating primaquine.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 6 mg base/5 mL oral suspension may be made using tablets. Crush ten 15 mg base tablets and reduce to a fine powder. In small amounts, add a total of 10 mL Carboxymethylcellulose 1.5% and mix to a uniform paste; mix while adding Simple Syrup, NF to",
"     <b>",
"      almost",
"     </b>",
"     125 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 125 mL. Label \"shake well\" and \"refrigerate\". Stable 7 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/26/14757/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Guidelines for the Treatment of Malaria in the United States.\" Available at:",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Health Information for International Travel, 2010,\" Atlanta: U.S. Department of Health and Human Services, 2010. Available at:",
"      <a href=\"file://www.cdc.gov/travel/contentYellowBook.aspx\" target=\"_blank\">",
"       file://www.cdc.gov/travel/contentYellowBook.aspx",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"",
"      <i>",
"       Pneumocystis jiroveci",
"      </i>",
"      (Formerly",
"      <i>",
"       carinii",
"      </i>",
"      ) Pneumonia (PCP).\" Available at:",
"      <a href=\"file://www.dpd.cdc.gov/DPDx/HTML/PDF_Files/MedLetter/Pneumocystis%20jiroveci.pdf\" target=\"_blank\">",
"       file://www.dpd.cdc.gov/DPDx/HTML/PDF_Files/MedLetter/Pneumocystis%20jiroveci.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Treatment of Malaria (Guidelines for Clinicians).\" Available at:",
"      <a href=\"file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lynk A and Gold R, &ldquo;Review of 40 Children With Imported Malaria,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(11):745-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/26/14757/abstract-text/2594448/pubmed\" id=\"2594448\" target=\"_blank\">",
"        2594448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12726 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14757=[""].join("\n");
var outline_f14_26_14757=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709346\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049518\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049511\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213228\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213214\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049522\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049514\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049521\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6704513\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213270\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049525\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049510\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6007553\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213260\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213223\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13801098\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049517\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049509\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049524\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049516\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806435\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12726\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12726|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=related_link\">",
"      Primaquine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/37/30292?source=related_link\">",
"      Primaquine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_26_14758="Overview of the classification and management of cancers of unknown primary site";
var content_f14_26_14758=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the classification and management of cancers of unknown primary site",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/26/14758/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/26/14758/contributors\">",
"     John D Hainsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/26/14758/contributors\">",
"     F Anthony Greco, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/26/14758/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/26/14758/contributors\">",
"     George P Canellos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/26/14758/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/26/14758/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/26/14758/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of unknown primary site (CUP) is a relatively common clinical entity, accounting for 4 to 5 percent of all invasive cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14758/abstract/1\">",
"     1",
"    </a>",
"    ]. Within this category, tumors from many primary sites with varying biology are represented. This heterogeneity has made the design and interpretation of clinical studies difficult.",
"   </p>",
"   <p>",
"    Patients with CUPs typically present with symptoms referable to metastases. The initial work-up, including physical examination, laboratory studies, and imaging procedures, often fails to identify the primary site.",
"   </p>",
"   <p>",
"    Patients are initially placed into one of five categories based upon the light microscopic examination of the initial biopsy. This classification is then used to guide further evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenocarcinoma",
"     </li>",
"     <li>",
"      Squamous cell carcinoma",
"     </li>",
"     <li>",
"      Neuroendocrine carcinoma, which may be either well differentiated or poorly differentiated",
"     </li>",
"     <li>",
"      Poorly differentiated tumors, most of which are recognized as carcinomas by histologic examination. Less frequently, the lineage (carcinoma, lymphoma, sarcoma, melanoma, germ cell tumor) is unclear after light microscopic examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These histologic groups vary with respect to clinical characteristics, diagnostic approach, treatment, and prognosis. An overview of these issues for each subset is presented here, and the evaluation and treatment of each of these subgroups is discussed in more detail separately. (See appropriate topics as noted below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial work-up of patients presenting with a presumed CUP should not be exhaustive. Instead, the evaluation for likely primary sites should focus on those tumor types where specific therapy can have a positive impact on the clinical outcome.",
"   </p>",
"   <p>",
"    This initial evaluation should include, at a minimum, a thorough history and physical examination, complete blood count, urinalysis, basic serum chemistries, a chest radiograph, and computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis. In women, the evaluation should include a pelvic examination and mammography. In men, assessment should incorporate a prostate examination and measurement of serum prostate specific antigen (PSA).",
"   </p>",
"   <p>",
"    The choice of further diagnostic procedures that are likely to clarify the diagnosis depends upon the interpretation of the initial biopsy sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ADENOCARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenocarcinomas of unknown primary site constitute approximately 70 percent of CUPs. The clinical presentation of patients with adenocarcinoma is determined by the sites of tumor involvement, which frequently include the liver, lungs, lymph nodes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bones. Initial clinical studies should focus primarily on determining the extent of metastatic disease and should incorporate the information derived from specialized pathologic studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link\">",
"     \"Adenocarcinoma of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In autopsy series of patients with adenocarcinoma of unknown primary site, the most frequently identified malignancies were lung, pancreas, hepatobiliary tree, and kidney, together accounting for approximately two-thirds of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14758/abstract/2\">",
"     2",
"    </a>",
"    ]. However, tumors may arise from a wide variety of other primary sites. Adenocarcinomas of the breast and prostate are relatively infrequent, despite being the most common cancers in women and men, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14758/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies are useful in identifying the anatomic primary site and thus guiding therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal CT, which suggests a specific primary site in 10 to 35 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14758/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Positron emission tomography (PET), which results in the identification of a primary site in 20 to 30 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14758/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A serum PSA determination in men. Tumors can also be stained immunohistochemically to detect the presence of PSA.",
"     </li>",
"     <li>",
"      Mammography and breast MRI in women with axillary lymphadenopathy compatible with metastatic breast cancer. Immunochemical staining may detect the expression of breast cancer-specific markers such as estrogen and progesterone receptors, mammaglobin, and gross cystic duct fluid protein in women. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=see_link&amp;anchor=H4#H4\">",
"       \"Axillary node metastases with occult primary breast cancer\", section on 'Initial diagnostic workup'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Additional signs or symptoms, such as a positive test for occult blood in stool, should be evaluated with appropriate radiographic or endoscopic studies. Colonoscopy should also be performed in patients with intra-abdominal metastases (liver, peritoneum) and pathologic findings",
"      <span class=\"nowrap\">",
"       (histology/immunohistochemistry)",
"      </span>",
"      typical of colon cancer, even in the absence of symptoms referable to the gastrointestinal tract. However, routine endoscopic evaluation of the upper",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lower gastrointestinal tract has a low yield in other asymptomatic patients, although occult primary lesions are occasionally identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Improved diagnostic methods should also be used to predict a tissue of tumor origin, although an anatomic primary tumor is not usually identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunohistochemistry, which may facilitate the identification of specific cancer types such as breast cancer or colorectal carcinoma (",
"      <a class=\"graphic graphic_table graphicRef56518 \" href=\"UTD.htm?29/14/29932\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Molecular tumor profiling, using a commercially available assay, predicts the tissue of origin in most patients, and has recently been shown to be useful in guiding site-specific therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Common tumor markers (carcinoma embryonic antigen [CEA], CA 19-9, CA 15-3, CA-125) generally are not useful as either diagnostic or prognostic tests. Markers are often elevated in the serum of patients with adenocarcinoma of unknown primary site, and serial measurement may be useful in following the response to therapy for individual tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link\">",
"     \"Screening for ovarian cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NEUROENDOCRINE TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroendocrine carcinomas of unknown primary site comprise about 1 percent of CUPs and can occur in a variety of sites (",
"    <a class=\"graphic graphic_table graphicRef76723 \" href=\"UTD.htm?11/46/12011\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=see_link\">",
"     \"Neuroendocrine cancer of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2000 World Health Organization (WHO) classification system divides these tumors into low-grade and high-grade malignancies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-grade neuroendocrine carcinoma &mdash; Metastatic carcinoid or islet cell tumors occasionally present without an obvious primary site, usually with liver metastases. In some patients, primary sites can subsequently be identified in the intestine or pancreas.",
"     </li>",
"     <li>",
"      High-grade neuroendocrine carcinoma &mdash; Most patients with high-grade neuroendocrine carcinoma have an aggressive malignancy, usually with metastases in multiple sites [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14758/abstract/8\">",
"       8",
"      </a>",
"      ]. Lymph nodes in the retroperitoneum and mediastinum are frequently involved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients in this group have metastatic small cell anaplastic carcinoma, which often represents a primary bronchogenic malignancy. CT of the chest and fiberoptic bronchoscopy usually can identify the primary site. Small cell carcinomas have also been described arising in a wide range of extrapulmonary sites include the salivary glands, esophagus, bladder, ovary, prostate, and cervix, among others. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=see_link\">",
"     \"Extrapulmonary small cell cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other high-grade neuroendocrine malignancies are poorly differentiated neuroendocrine carcinomas that exhibit neuroendocrine features on electron microscopy or immunohistochemistry but are not sufficiently differentiated to suggest the diagnosis of a small cell bronchogenic cancer or a",
"    <span class=\"nowrap\">",
"     carcinoid/islet",
"    </span>",
"    cell tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9096?source=see_link\">",
"     \"Poorly differentiated cancer from an unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SQUAMOUS CELL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma (SCC) is uncommon in the absence of an obvious primary tumor, except for patients who present with a neck mass. Overall, these constitute about 5 percent of CUPs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15459?source=see_link\">",
"     \"Squamous cell carcinoma of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation and subsequent diagnostic evaluation of such patients depends upon the predominant area of the metastasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper and midcervical lymphadenopathy &mdash; Upper and midcervical lymphadenopathy most frequently is due to cancer of the head and neck. Further evaluation should include CT of the head and neck, direct laryngoscopy, and nasopharyngoscopy. PET scanning should be performed if a primary site cannot be identified by CT or endoscopy.",
"     </li>",
"     <li>",
"      Inguinal lymphadenopathy &mdash; Most patients with SCC involving inguinal lymph nodes have a detectable primary site in the genital or anorectal area. In women, careful examination of the vulva, vagina, and cervix is important. Careful inspection of the penis should be performed in men. Digital rectal examination and anoscopy should be performed in both sexes.",
"     </li>",
"     <li>",
"      Adenopathy at other sites &mdash; Lymphadenopathy at sites other than cervical, supraclavicular, or inguinal nodes usually represents metastasis from a primary lung cancer. These patients should be evaluated with CT of the chest and fiberoptic bronchoscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunohistochemical studies and electron microscopy are of little value in identifying the primary site for patients with squamous cell carcinoma of unknown primary site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568147757\">",
"    <span class=\"h1\">",
"     POORLY DIFFERENTIATED CANCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 to 25 percent of all cancers of unknown primary site have poorly differentiated histology. About 80 percent of these can be recognized as poorly differentiated carcinoma by light microscopic examination. The remainder are termed &ldquo;poorly differentiated neoplasm&rdquo; after initial examination, implying that the pathologist is confident of the diagnosis of malignancy but cannot distinguish between a carcinoma, sarcoma, melanoma, or hematologic malignancy based upon light microscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9096?source=see_link\">",
"     \"Poorly differentiated cancer from an unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional pathologic evaluation is essential in all poorly differentiated cancers of unknown primary site. The group of cancers initially termed &ldquo;poorly differentiated neoplasm&rdquo; contains a number of highly treatable entities, including lymphoma and germ cell tumor. The identity of tumors called &ldquo;poorly differentiated carcinoma&rdquo; by light microscopy can also be clarified. This group contains poorly differentiated neuroendocrine carcinomas and occasionally non-carcinomas. Additional pathologic studies are almost always successful in identifying the lineage of these tumors; these studies may include immunohistochemistry, electron microscopy, molecular tumor profiling, and chromosome analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9096?source=see_link&amp;anchor=H2#H2\">",
"     \"Poorly differentiated cancer from an unknown primary site\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosing an occult germ cell tumor is of particular importance in this group, because of the responsiveness of germ cell tumors to chemotherapy. In addition to specialized pathologic studies, elevated serum concentrations of human chorionic gonadotropin (hCG) or alpha-fetoprotein (AFP) may suggest the diagnosis of extragonadal germ cell tumor of unknown primary site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a primary site can be identified or is strongly suggested in a patient with CUP, treatment is based upon the usual treatment for advanced cancer arising from that site. While regional disease is amenable to surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation, systemic therapy should be considered for disseminated disease.",
"   </p>",
"   <p>",
"    Accurate diagnostic classification can lead to individualized therapy for specific subgroups of patients with CUP (",
"    <a class=\"graphic graphic_table graphicRef52585 \" href=\"UTD.htm?9/16/9484\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with adenocarcinoma and isolated axillary lymphadenopathy, who may benefit from treatment as stage II breast cancer (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=see_link\">",
"       \"Axillary node metastases with occult primary breast cancer\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Women with peritoneal carcinomatosis, who may respond to treatment patterned after that used for stage III ovarian cancer (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link&amp;anchor=H10#H10\">",
"       \"Adenocarcinoma of unknown primary site\", section on 'Women with peritoneal carcinomatosis'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with a clinical features and pathologic studies consistent with a colorectal primary tumor may respond well to chemotherapy regimens directed against that tumor. This profile includes metastases involving liver",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peritoneum, typical histology, and immunohistochemical staining",
"      <span class=\"nowrap\">",
"       CK20-positive/CK7-negative",
"      </span>",
"      or CDX2-positive (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link&amp;anchor=H519862394#H519862394\">",
"       \"Adenocarcinoma of unknown primary site\", section on 'Patients with a colon cancer profile'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Men with blastic bone metastases or an elevated serum PSA, in whom treatment for metastatic prostate cancer may be useful (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"       \"Overview of the treatment of disseminated prostate cancer\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Squamous cell carcinoma limited to cervical lymph nodes, which may be a manifestation of locally advanced head and neck cancer with an occult primary, and should be treated as a locally advanced head and neck cancer (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15459?source=see_link\">",
"       \"Squamous cell carcinoma of unknown primary site\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Young men with poorly differentiated mediastinal or retroperitoneal tumors that may respond to treatment as an extragonadal germ cell tumor (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"       \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Well differentiated neuroendocrine carcinoma, for which treatment is similar that used for advanced carcinoid tumor (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=see_link\">",
"       \"Neuroendocrine cancer of unknown primary site\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Poorly differentiated neuroendocrine carcinoma, for which treatment is similar to that used for small cell lung cancer (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=see_link\">",
"       \"Neuroendocrine cancer of unknown primary site\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=see_link\">",
"       \"Extrapulmonary small cell cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most cases, the primary site cannot be identified, and the patient does not fall into one of the above subgroups. For these patients, empiric chemotherapy has been considered the standard treatment. Such treatment, usually with combinations containing a platinum agent plus one of the newer cytotoxic agents (taxanes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ), has produced median survivals of 7 to 10 months, and 2-year survival rates of 20 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14758/abstract/9\">",
"     9",
"    </a>",
"    ]. This treatment represents an improvement when compared to historical results (median survival 4 to 6 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14758/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]; however, the majority of patients derive only modest benefit. In addition, the improvement of therapy for many advanced solid tumors makes it increasingly unlikely that optimal therapeutic results can be achieved using a single &ldquo;broad-spectrum&rdquo; chemotherapy regimen.",
"   </p>",
"   <p>",
"    With improvements in diagnosis, particularly molecular tumor profiling, a tissue of origin can be predicted in the majority of patients, even though the anatomic primary site cannot be identified. Although data are still developing, site-specific treatment based on molecular tumor profiling assay predictions appears to improve treatment results for CUP patients who do not fit into a specific treatable subset [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14758/abstract/12\">",
"     12",
"    </a>",
"    ]. Benefits of this approach are most evident in patients predicted to have treatment-responsive tumor types. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link\">",
"     \"Adenocarcinoma of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current recommendations for treatment of patients with CUP are diagrammed in Figure 1 (",
"    <a class=\"graphic graphic_algorithm graphicRef86664 \" href=\"UTD.htm?21/19/21822\">",
"     algorithm 1",
"    </a>",
"    ). Molecular tumor profiling, followed by site-specific therapy, should now be a part of the standard diagnostic evaluation for CUP patients who do not fit into a specific subset. Empiric chemotherapy should be considered for patients whose tumors are unclassifiable by molecular tumor profiling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of unknown primary accounts for up to 4 to 5 percent of all cancer diagnoses. Despite extensive clinical, laboratory, and imaging evaluation, the primary site remains unidentified in the majority of cases.",
"   </p>",
"   <p>",
"    Cancers of unknown primary can be classified into five categories (see",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenocarcinoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link\">",
"       \"Adenocarcinoma of unknown primary site\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Squamous cell carcinoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15459?source=see_link\">",
"       \"Squamous cell carcinoma of unknown primary site\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neuroendocrine carcinoma, which may be either well differentiated or poorly differentiated (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=see_link\">",
"       \"Neuroendocrine cancer of unknown primary site\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Poorly differentiated cancer (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9096?source=see_link\">",
"       \"Poorly differentiated cancer from an unknown primary site\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Appropriate classification, based upon all available evidence, is essential to identify patients for whom a specific treatment may be particularly useful (",
"    <a class=\"graphic graphic_table graphicRef52585 \" href=\"UTD.htm?9/16/9484\">",
"     table 3",
"    </a>",
"    ). For the remainder of patients, molecular tumor profiling should be used to provide a tissue of origin prediction, with subsequent site-specific therapy. Empiric chemotherapy should be considered for patients with unclassifiable tumors.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14758/abstract/1\">",
"      Greco FA, Hainsworth JD. Introduction: unknown primary cancer. Semin Oncol 2009; 36:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14758/abstract/2\">",
"      Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007; 43:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14758/abstract/3\">",
"      Nystrom JS, Weiner JM, Heffelfinger-Juttner J, et al. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 1977; 4:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14758/abstract/4\">",
"      Karsell PR, Sheedy PF 2nd, O'Connell MJ. Computed tomography in search of cancer of unknown origin. JAMA 1982; 248:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14758/abstract/5\">",
"      McMillan JH, Levine E, Stephens RH. Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study. Radiology 1982; 143:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14758/abstract/6\">",
"      Bohuslavizki KH, Klutmann S, Kr&ouml;ger S, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000; 41:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14758/abstract/7\">",
"      Gutzeit A, Antoch G, K&uuml;hl H, et al. Unknown primary tumors: detection with dual-modality PET/CT--initial experience. Radiology 2005; 234:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14758/abstract/8\">",
"      Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med 1988; 109:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14758/abstract/9\">",
"      Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol 2009; 36:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14758/abstract/10\">",
"      Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer 1986; 57:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14758/abstract/11\">",
"      Muir C. Cancer of unknown primary site. Cancer 1995; 75:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14758/abstract/12\">",
"      Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 2013; 31:217.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4878 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.150-851E2265C2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14758=[""].join("\n");
var outline_f14_26_14758=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ADENOCARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NEUROENDOCRINE TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SQUAMOUS CELL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1568147757\">",
"      POORLY DIFFERENTIATED CANCERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4878\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4878|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?21/19/21822\" title=\"algorithm 1\">",
"      Treatment of patients with carcinoma of unknown primary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4878|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29932\" title=\"table 1\">",
"      Immunohistochemistry CUP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/46/12011\" title=\"table 2\">",
"      Neuroendocr tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/16/9484\" title=\"table 3\">",
"      CUP treatment schema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=related_link\">",
"      Adenocarcinoma of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=related_link\">",
"      Axillary node metastases with occult primary breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=related_link\">",
"      Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=related_link\">",
"      Extrapulmonary small cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=related_link\">",
"      Neuroendocrine cancer of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9096?source=related_link\">",
"      Poorly differentiated cancer from an unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15459?source=related_link\">",
"      Squamous cell carcinoma of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_26_14759="Clinical manifestations and diagnosis of achalasia";
var content_f14_26_14759=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of achalasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/26/14759/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/26/14759/contributors\">",
"     Stuart J Spechler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/26/14759/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/26/14759/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/26/14759/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/26/14759/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/26/14759/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 31, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achalasia (a Greek term that means \"does not relax\") is a disease of unknown cause in which there is a loss of peristalsis in the distal esophagus (whose musculature is comprised predominantly of smooth muscle) and a failure of lower esophageal sphincter (LES) relaxation with swallowing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=see_link\">",
"     \"Pathophysiology and etiology of achalasia\"",
"    </a>",
"    .) Although both of these abnormalities impair esophageal emptying, the symptoms and signs of achalasia are due primarily to the defect in LES relaxation. The relentless LES contraction in achalasia causes functional obstruction of the esophagus that persists until the hydrostatic pressure of the retained material exceeds the pressure generated by the sphincter muscle.",
"   </p>",
"   <p>",
"    Some reports suggest that it might be more appropriate to use the term \"esophagogastric junction (EGJ) relaxation\" rather than \"LES relaxation\" because the pressure measured by a sensor positioned at the LES usually records a combination of pressures generated by both the esophageal sphincter muscle (ie, the LES itself) and by the crural diaphragm that encircles the distal esophagus. The term LES will continue to be used here since it is used in the majority of reports on the manometric features of achalasia.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of achalasia will be reviewed here. The treatment of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=see_link\">",
"     \"Overview of the treatment of achalasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12810?source=see_link\">",
"     \"Pneumatic dilation and botulinum toxin injection for achalasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19001?source=see_link\">",
"     \"Operative management of achalasia: Laparoscopic and open Heller myotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Gastroenterological Association (AGA) guideline for dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/1\">",
"     1",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achalasia is an uncommon disorder that has an annual incidence of approximately 1.6 cases per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/2\">",
"     2",
"    </a>",
"    ]. Men and women are affected with equal frequency. The disease can occur at virtually any age, but onset before adolescence is decidedly unusual. Achalasia is usually diagnosed in patients who are between the ages of 25 and 60 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3357149\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphagia for solids (91 percent) and liquids (85 percent) is the primary clinical feature of achalasia (",
"    <a class=\"graphic graphic_figure graphicRef62139 \" href=\"UTD.htm?25/24/25998\">",
"     figure 1",
"    </a>",
"    ). Although dysphagia for liquids can occur in patients with other esophageal motility disorders (eg, progressive systemic sclerosis), this symptom is most characteristic of achalasia and strongly suggests the diagnosis.",
"   </p>",
"   <p>",
"    Difficulty belching has been described in approximately 85 percent of patients, although few describe this symptom spontaneously (ie, without specific prompting from the physician). The difficulty with belching may be due to a defect in relaxation of the upper esophageal sphincter, which normally occurs when the esophagus is distended by gas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=see_link\">",
"     \"Pathophysiology and etiology of achalasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weight loss, regurgitation, chest pain, and heartburn occur in approximately 40 to 60 percent of patients (",
"    <a class=\"graphic graphic_figure graphicRef62139 \" href=\"UTD.htm?25/24/25998\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The degree of weight loss is usually mild, in the range of 5 to 10 kg, although profound weight loss can be seen.",
"     </li>",
"     <li>",
"      Regurgitation of material retained in the flaccid esophagus may be troublesome, especially during recumbency at night, and may result in aspiration. Some patients induce regurgitation to relieve a retrosternal feeling of fullness after a meal.",
"     </li>",
"     <li>",
"      Chest pain is occasionally the presenting symptom of achalasia. The presence of pain cannot be predicted reliably from manometric or radiographic findings and pain often does not improve after pneumatic dilatation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/3\">",
"       3",
"      </a>",
"      ]. Chest pain is more common in younger patients, and tends to diminish over the course of several years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=see_link\">",
"       \"Chest pain of esophageal origin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The sensation of heartburn, the cardinal symptom of gastroesophageal reflux disease (GERD), occurs with surprising frequency in achalasia [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/4\">",
"       4",
"      </a>",
"      ]. Patients with this symptom often have lower LES pressures than those without heartburn; furthermore, heartburn may disappear with the onset of dysphagia, suggesting that such patients had underlying GERD before developing achalasia [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/4\">",
"       4",
"      </a>",
"      ]. Heartburn may also result from direct irritation of the esophageal lining by food, pills, or lactate production by bacterial fermentation of retained carbohydrate [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Affected patients may eat more slowly and adopt specific maneuvers such as lifting the neck or throwing the shoulders back in order to enhance esophageal emptying.",
"     </li>",
"     <li>",
"      Globus sensation (a lump in the throat) has been reported as a presenting symptom. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21814?source=see_link\">",
"       \"Globus sensation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hiccups are common and probably result from obstruction of the distal esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An association with adrenal glucocorticoid deficiency and alacrima (triple A syndrome or Allgrove syndrome) has been described in children with achalasia [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/7\">",
"       7",
"      </a>",
"      ]. It is possible that a variant of this syndrome is present in adults since in one report, 4 of 20 of adult patients (20 percent) with achalasia were found to have deficient tear production [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262982107\">",
"    <span class=\"h2\">",
"     Risk of esophageal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with achalasia are generally thought to be at substantially increased risk for developing esophageal cancer, which is typically squamous cell type, although studies have also shown an increased risk of esophageal adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A population-based study in Sweden found that the risk of esophageal cancer was extremely high in the first year after diagnosis of achalasia (due to tumor producing distal obstruction and simulating achalasia); over the long-term, the risk was increased 16-fold compared with population controls [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/9\">",
"       9",
"      </a>",
"      ]. Cancer was diagnosed an average of 14 years after the diagnosis of achalasia. It was estimated that annual surveillance endoscopy after the first year would be required in 406 men and 2200 women to detect one cancer.",
"     </li>",
"     <li>",
"      A study from the Netherlands included 448 patients with achalasia with a median follow-up of 9.6 years [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/12\">",
"       12",
"      </a>",
"      ]. Esophageal cancer developed in 15 patients (3.3 percent) after a mean symptom duration of 13 years (hazard ratio 28 compared with an age- and sex-matched cohort).",
"     </li>",
"     <li>",
"      There is a paucity of long-term data on the development of esophageal cancer following a Heller myotomy for achalasia. In a retrospective review of 226 patients surgically treated for achalasia, four (1.8 percent) developed a squamous cell esophageal carcinoma at 2, 8, 13, and 18 years after the operation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19001?source=see_link&amp;anchor=H37208975#H37208975\">",
"       \"Operative management of achalasia: Laparoscopic and open Heller myotomy\", section on 'Other complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      However, some series note no increase in esophageal cancer risk, particularly with early treatment of achalasia [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A guideline issued by the American Society of Gastrointestinal Endoscopy suggests that there are insufficient data to support routine endoscopic surveillance for patients with achalasia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/16\">",
"     16",
"    </a>",
"    ]. If surveillance were to be considered, it would be reasonable to initiate it 15 years after onset of symptoms, but the subsequent surveillance interval is not defined. We do",
"    <strong>",
"     not",
"    </strong>",
"    feel that the risk is high enough to warrant regular endoscopic surveillance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of achalasia often are insidious in onset and gradual in progression. As a result, patients typically experience symptoms for years before seeking medical attention. In one series of 87 consecutive patients with newly diagnosed achalasia, the mean duration of symptoms was 4.7 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/17\">",
"     17",
"    </a>",
"    ]. The delay in diagnosis was due to misinterpretation of typical findings by physicians rather than atypical clinical manifestations. Many patients are treated for other disorders such as gastroesophageal reflux disease before the diagnosis of achalasia is made [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have a clinical history suggestive of achalasia require radiographic, manometric, and endoscopic evaluation to confirm the diagnosis. The diagnosis is occasionally suggested on a plain radiograph of the chest that shows widening of the mediastinum due to the dilated esophagus, and absence of the normal gastric air bubble caused by the failure of LES relaxation that prevents air from entering the stomach (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75115 \" href=\"UTD.htm?10/2/10276\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow is the primary screening test when achalasia is suspected on clinical grounds. The diagnostic accuracy of barium swallow for achalasia is approximately 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/19\">",
"     19",
"    </a>",
"    ]. The barium swallow typically shows a dilated esophagus that terminates in a beak-like narrowing caused by the persistently contracted lower esophageal sphincter (LES) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54252 graphicRef53672 \" href=\"UTD.htm?40/36/41538\">",
"     image 2A-B",
"    </a>",
"    ). In some cases, the dilation is so profound that the esophagus assumes a sigmoid shape.",
"   </p>",
"   <p>",
"    Fluoroscopy reveals the absence of peristalsis in the smooth muscle portion of the esophagus. In some patients, purposeless, spastic contractions are observed in the esophageal body (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78857 \" href=\"UTD.htm?41/45/42718\">",
"     image 3",
"    </a>",
"    ). Some radiologists call the latter condition \"vigorous\" achalasia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/20\">",
"     20",
"    </a>",
"    ]. However, vigorous achalasia is usually defined by manometric criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Standard manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinical and radiographic findings may strongly suggest the diagnosis of achalasia, a manometric examination is suggested for confirmation in virtually all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/21\">",
"     21",
"    </a>",
"    ]. There are three characteristic manometric features of achalasia, although a number of variants have been described (",
"    <a class=\"graphic graphic_figure graphicRef75809 \" href=\"UTD.htm?19/57/20370\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated resting LES pressure &ndash; In the LES, the loss of inhibitory neurons typically causes LES pressures to rise to hypertensive levels (above 45 mmHg).",
"     </li>",
"     <li>",
"      Incomplete LES relaxation &ndash; Normally, there is complete relaxation of the LES after a swallow (to a level &lt;8 mmHg above gastric pressure); by contrast, LES relaxation in response to a swallow may be incomplete or absent in achalasia. This manometric finding distinguishes achalasia from other disorders associated with aperistalsis.",
"     </li>",
"     <li>",
"      Aperistalsis &ndash; Aperistalsis is seen in the smooth muscle portion of the body of the esophagus. Swallows may elicit no esophageal contraction or may be followed by simultaneous contractions. The esophagus may also contract spontaneously in a simultaneous fashion. For most patients, whatever esophageal contractions remain are of low amplitude; in some cases, however, the simultaneous esophageal contractions have higher amplitudes. Such patients are said to have \"vigorous\" achalasia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vigorous achalasia has been defined by the presence of \"normal\" to high-amplitude simultaneous esophageal body contractions in the presence of a nonrelaxing LES [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/23\">",
"     23",
"    </a>",
"    ]. The amplitudes of preserved esophageal body contractions used to define vigorous achalasia have ranged from 37 to 60 mmHg. Long duration esophageal body contractions may also be seen.",
"   </p>",
"   <p>",
"    The importance of the radiographic or manometric demonstration of vigorous achalasia remains controversial. It was initially thought that chest pain might be more prominent in patients with vigorous achalasia; however, later reports were unable to clinically distinguish vigorous from classic achalasia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have suggested that vigorous achalasia may represent an early form of achalasia in which intramural ganglion cells may still be prevalent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/24\">",
"     24",
"    </a>",
"    ], and that patients with vigorous achalasia may exhibit a better response to therapy with botulinum toxin injection than those with classic achalasia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/25\">",
"     25",
"    </a>",
"    ]. These observations require confirmation; at present, the distinction between vigorous and classic achalasia appears to have little clinical importance.",
"   </p>",
"   <p>",
"    Another manometric abnormality often observed in achalasia is that resting pressure in the body of the esophagus is slightly higher than that in the stomach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     High-resolution manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with conventional esophageal manometry catheters, which typically have three to eight sensors spaced at intervals of 3 to 5 cm, high resolution manometry catheters use a much larger number of sensors spaced at closer intervals (eg, 36 sensors at 1 cm intervals). The data collected by these multiple sensors are processed using computer algorithms to display the manometric study in the form of color-coded graphs. When the data are displayed with pressure topography plots, the resulting technology is called high-resolution esophageal pressure topography (HREPT). Findings on HREPT correlate with those of standard manometry, but HREPT provides enhanced detail in the characterization of achalasia, esophageal spasm, nutcracker esophagus, and the morphology of the esophageal gastric junction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/26\">",
"     26",
"    </a>",
"    ]. A classification system, the \"Chicago Classification,\" has been developed to categorize esophageal motility disorders using HREPT (",
"    <a class=\"graphic graphic_table graphicRef59779 \" href=\"UTD.htm?14/23/14717\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-resolution manometry has been used to subtype achalasia. One study that examined 99 patients with achalasia identified three subtypes by HREPT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/28\">",
"     28",
"    </a>",
"    ]. All the subtypes exhibited incomplete LES relaxation (referred to as EGJ relaxation), but they could be distinguished by the swallow-induced pressure response in the body of the esophagus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In type I (classic) achalasia, swallowing resulted in no significant change in esophageal pressurization.",
"     </li>",
"     <li>",
"      In type II achalasia, swallowing resulted in simultaneous pressurization that spanned the entire length of the esophagus.",
"     </li>",
"     <li>",
"      In type III (spastic) achalasia, swallowing resulted in abnormal, lumen-obliterating contractions (spasms).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Responses to all types of achalasia treatment (botulinum toxin injection, pneumatic dilation, surgical myotomy) were best in the type II patients and worst in the type III patients. Further studies are needed to confirm these observations that high-resolution manometry can be used to predict the response to therapy in achalasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic evaluation is generally recommended for patients with achalasia, primarily to exclude malignancies at the esophagogastric junction that can mimic primary achalasia clinically, radiographically, and manometrically (so called \"pseudoachalasia\"). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=see_link\">",
"     \"Pathophysiology and etiology of achalasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopy in achalasia typically reveals a dilated esophagus that often contains residual material. The esophageal mucosa usually appears normal, although inflammation and ulceration may result from irritation caused by retained food or pills. In addition, esophageal stasis predisposes to candida infection that may be apparent as adherent whitish plaques on the mucosal surface.",
"   </p>",
"   <p>",
"    The LES does not open spontaneously to allow effortless passage of the endoscope into the stomach but, unlike obstruction caused by neoplasms or fibrotic strictures, the contracted LES of achalasia usually can be traversed easily with gentle pressure on the endoscope. The esophagogastric junction should be carefully examined for evidence of neoplasm and examination of the gastric cardia and fundus is important since gastric adenocarcinoma is the most common neoplasm associated with pseudoachalasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancy and a variety of nonmalignant diseases can cause an achalasia-like motility disorder (",
"    <a class=\"graphic graphic_table graphicRef71111 \" href=\"UTD.htm?4/0/4107\">",
"     table 2",
"    </a>",
"    ). These are generally much less common than idiopathic achalasia, except for Chagas disease in endemic areas in Central and South America. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=see_link\">",
"     \"Pathophysiology and etiology of achalasia\"",
"    </a>",
"    .) Certain features increase the likelihood that the patient has pseudoachalasia due to malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration of symptoms less than six months",
"     </li>",
"     <li>",
"      Presentation after age 60",
"     </li>",
"     <li>",
"      Excessive weight loss in relation to the duration of symptoms",
"     </li>",
"     <li>",
"      Difficult passage of the endoscope through the gastroesophageal junction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Esophageal manometry does not discriminate primary (idiopathic) achalasia from pseudoachalasia. However, CT scan may suggest malignancy if there is marked (greater than 10 mm)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    asymmetric esophageal wall thickening [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/30\">",
"     30",
"    </a>",
"    ]. Endoscopy with biopsy is not always diagnostic because the tumors are often infiltrative [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/29\">",
"     29",
"    </a>",
"    ] and do not extend through the mucosa to the lumen. Thus, repeated evaluations and biopsies are recommended when there is a high suspicion of malignancy.",
"   </p>",
"   <p>",
"    Endoscopic ultrasonography (EUS) may show thickening of the longitudinal and circular smooth muscle layers of the LES, but this finding is not sufficiently specific to distinguish patients with achalasia from controls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14759/abstract/31\">",
"     31",
"    </a>",
"    ]. EUS is useful for characterizing tumors of the distal esophagus and cardia, and generally is recommended when pseudoachalasia due to malignancy is suspected. Nevertheless, the accuracy of EUS for distinguishing achalasia from pseudoachalasia is not yet established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/50/20258?source=see_link\">",
"       \"Patient information: Achalasia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/55/2934?source=see_link\">",
"       \"Patient information: Achalasia (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21885408\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Achalasia is a disease of unknown cause in which there is a loss of peristalsis in the distal esophagus and a failure of lower esophageal sphincter (LES) relaxation with swallowing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=see_link\">",
"       \"Pathophysiology and etiology of achalasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dysphagia for solids (91 percent) and liquids (85 percent) is the primary clinical feature of achalasia. Weight loss, regurgitation, chest pain, and heartburn occur in approximately 40 to 60 percent of patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with achalasia are at substantially increased risk for developing esophageal cancer, which is typically squamous cell type. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have a clinical history suggestive of achalasia require radiographic, manometric, and endoscopic evaluation to confirm the diagnosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      swallow is the primary screening test when achalasia is suspected on clinical grounds. The barium swallow typically shows a dilated esophagus that terminates in a beak-like narrowing caused by the persistently contracted LES (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54252 graphicRef53672 \" href=\"UTD.htm?40/36/41538\">",
"       image 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Radiographic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although clinical and radiographic findings may strongly suggest the diagnosis of achalasia, a manometric examination is suggested for confirmation in virtually all cases. Findings on standard manometry include elevated LES pressure, incomplete LES relaxation during swallowing, and aperistalsis of the esophageal body. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Standard manometry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopic evaluation is generally recommended for patients with achalasia, primarily to exclude malignancies at the esophagogastric junction that can mimic primary achalasia clinically, radiographically, and manometrically (so called \"pseudoachalasia\"). Endoscopy in achalasia typically reveals a dilated esophagus that often contains residual material. &nbsp;(See",
"      <a class=\"local\" href=\"#H7\">",
"       'Endoscopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/1\">",
"      Spechler SJ. American gastroenterological association medical position statement on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology 1999; 117:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/2\">",
"      Sadowski DC, Ackah F, Jiang B, Svenson LW. Achalasia: incidence, prevalence and survival. A population-based study. Neurogastroenterol Motil 2010; 22:e256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/3\">",
"      Eckardt VF, Stauf B, Bernhard G. Chest pain in achalasia: patient characteristics and clinical course. Gastroenterology 1999; 116:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/4\">",
"      Spechler SJ, Souza RF, Rosenberg SJ, et al. Heartburn in patients with achalasia. Gut 1995; 37:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/5\">",
"      Burke CA, Achkar E, Falk GW. Effect of pneumatic dilation on gastroesophageal reflux in achalasia. Dig Dis Sci 1997; 42:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/6\">",
"      Seeman H, Traube M. Hiccups and achalasia. Ann Intern Med 1991; 115:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/7\">",
"      Allgrove J, Clayden GS, Grant DB, Macaulay JC. Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. Lancet 1978; 1:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/8\">",
"      Verma S, Brown S, Dakkak M, Bennett JR. Association of adult achalasia and alacrima. Dig Dis Sci 1999; 44:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/9\">",
"      Sandler RS, Nyr&eacute;n O, Ekbom A, et al. The risk of esophageal cancer in patients with achalasia. A population-based study. JAMA 1995; 274:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/10\">",
"      Csendes A, Braghetto I, Burdiles P, et al. Very late results of esophagomyotomy for patients with achalasia: clinical, endoscopic, histologic, manometric, and acid reflux studies in 67 patients for a mean follow-up of 190 months. Ann Surg 2006; 243:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/11\">",
"      Streitz JM Jr, Ellis FH Jr, Gibb SP, Heatley GM. Achalasia and squamous cell carcinoma of the esophagus: analysis of 241 patients. Ann Thorac Surg 1995; 59:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/12\">",
"      Leeuwenburgh I, Scholten P, Alderliesten J, et al. Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J Gastroenterol 2010; 105:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/13\">",
"      Zendehdel K, Nyr&eacute;n O, Edberg A, Ye W. Risk of esophageal adenocarcinoma in achalasia patients, a retrospective cohort study in Sweden. Am J Gastroenterol 2011; 106:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/14\">",
"      Zaninotto G, Rizzetto C, Zambon P, et al. Long-term outcome and risk of oesophageal cancer after surgery for achalasia. Br J Surg 2008; 95:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/15\">",
"      Arber N, Grossman A, Lurie B, et al. Epidemiology of achalasia in central Israel. Rarity of esophageal cancer. Dig Dis Sci 1993; 38:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/16\">",
"      Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/17\">",
"      Eckardt VF, K&ouml;hne U, Junginger T, Westermeier T. Risk factors for diagnostic delay in achalasia. Dig Dis Sci 1997; 42:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/18\">",
"      Howard PJ, Maher L, Pryde A, et al. Five year prospective study of the incidence, clinical features, and diagnosis of achalasia in Edinburgh. Gut 1992; 33:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/19\">",
"      Ott DJ, Richter JE, Chen YM, et al. Esophageal radiography and manometry: correlation in 172 patients with dysphagia. AJR Am J Roentgenol 1987; 149:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/20\">",
"      Goldenberg SP, Burrell M, Fette GG, et al. Classic and vigorous achalasia: a comparison of manometric, radiographic, and clinical findings. Gastroenterology 1991; 101:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/21\">",
"      Reynolds JC, Parkman HP. Achalasia. Gastroenterol Clin North Am 1989; 18:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/22\">",
"      Hirano I, Tatum RP, Shi G, et al. Manometric heterogeneity in patients with idiopathic achalasia. Gastroenterology 2001; 120:789.",
"     </a>",
"    </li>",
"    <li>",
"     Hirano I. Pathophysiology of achalasia and diffuse esophageal spasm. GI Motility Online 2006; doi: 10.1038/gimo22.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/24\">",
"      Goldblum JR, Rice TW, Richter JE. Histopathologic features in esophagomyotomy specimens from patients with achalasia. Gastroenterology 1996; 111:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/25\">",
"      Pasricha PJ, Rai R, Ravich WJ, et al. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology 1996; 110:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/26\">",
"      Pandolfino JE, Ghosh SK, Rice J, et al. Classifying esophageal motility by pressure topography characteristics: a study of 400 patients and 75 controls. Am J Gastroenterol 2008; 103:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/27\">",
"      Kahrilas PJ, Ghosh SK, Pandolfino JE. Esophageal motility disorders in terms of pressure topography: the Chicago Classification. J Clin Gastroenterol 2008; 42:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/28\">",
"      Pandolfino JE, Kwiatek MA, Nealis T, et al. Achalasia: a new clinically relevant classification by high-resolution manometry. Gastroenterology 2008; 135:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/29\">",
"      Tracey JP, Traube M. Difficulties in the diagnosis of pseudoachalasia. Am J Gastroenterol 1994; 89:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/30\">",
"      Carter M, Deckmann RC, Smith RC, et al. Differentiation of achalasia from pseudoachalasia by computed tomography. Am J Gastroenterol 1997; 92:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14759/abstract/31\">",
"      Miller LS, Liu JB, Barbarevech CA, et al. High-resolution endoluminal sonography in achalasia. Gastrointest Endosc 1995; 42:545.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2268 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-7CA0D077E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14759=[""].join("\n");
var outline_f14_26_14759=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21885408\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3357149\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H262982107\">",
"      Risk of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Standard manometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      High-resolution manometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21885408\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2268\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2268|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/2/10276\" title=\"diagnostic image 1\">",
"      Achalasia PA Lat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/35/20016\" title=\"diagnostic image 2A\">",
"      Classic achalasia Ba swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/55/24446\" title=\"diagnostic image 2B\">",
"      Achalasia barium swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/45/42718\" title=\"diagnostic image 3\">",
"      Vigorous achalasia Ba swallow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2268|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/24/25998\" title=\"figure 1\">",
"      Symptoms of achalasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/57/20370\" title=\"figure 2\">",
"      Manometry in achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2268|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/23/14717\" title=\"table 1\">",
"      The Chicago Classification of esophageal motility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/0/4107\" title=\"table 2\">",
"      Diseases associated with achalasia-like motility disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=related_link\">",
"      Chest pain of esophageal origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21814?source=related_link\">",
"      Globus sensation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19001?source=related_link\">",
"      Operative management of achalasia: Laparoscopic and open Heller myotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=related_link\">",
"      Overview of the treatment of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=related_link\">",
"      Pathophysiology and etiology of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/55/2934?source=related_link\">",
"      Patient information: Achalasia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/50/20258?source=related_link\">",
"      Patient information: Achalasia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12810?source=related_link\">",
"      Pneumatic dilation and botulinum toxin injection for achalasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_26_14760="Acanthocytes or spur cells";
var content_f14_26_14760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acanthocytes (spur cells)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear shows multiple acanthocytes (spur cells). These cells have prominent irregular protrusions scattered over the surface in an asymmetrical pattern. They are often confused with echinocytes in which the protrusions are smaller and more regular.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14760=[""].join("\n");
var outline_f14_26_14760=null;
var title_f14_26_14761="EEG periodic lateralized epileptiform discharges PLEDS";
var content_f14_26_14761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Right hemisphere PLEDs: periodic lateralized epileptiform discharges",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 354px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chong DJ, Hirsch, LJ. Which EEG patterns warrant treatment in the critically ill? Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns. J Clin Neurophysiol 2005; 22:79. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14761=[""].join("\n");
var outline_f14_26_14761=null;
var title_f14_26_14762="Normal pressure hydrocephalus";
var content_f14_26_14762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Normal pressure hydrocephalus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/26/14762/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/26/14762/contributors\">",
"     Neill R Graff-Radford, MBBCh, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/26/14762/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/26/14762/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/26/14762/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/26/14762/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/26/14762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal pressure hydrocephalus (NPH) refers to a condition of pathologically enlarged ventricular size with normal opening pressures on lumbar puncture. NPH is distinguished from obstructive or noncommunicating hydrocephalus, in which there is a structural blockage of the cerebrospinal fluid (CSF) circulation within the ventricular system (eg, stenosis of aqueduct of Sylvius).",
"   </p>",
"   <p>",
"    NPH is associated with a classic triad of dementia, gait disturbance, and urinary incontinence. Because this clinical syndrome is potentially reversible by the placement of a ventriculoperitoneal shunt, it is important to recognize and accurately diagnose. However, there is little consensus regarding the diagnosis of NPH and the selection of patients for shunt placement [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic provides an overview of the epidemiology, clinical features, diagnosis, and management of NPH. Other dementia syndromes are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of normal pressure hydrocephalus (NPH) has varied in different studies from 2 to 20 per million per year [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These discrepancies probably reflect inconsistent definitions of NPH as well as differences among populations sampled.",
"   </p>",
"   <p>",
"    NPH occurs as an idiopathic or secondary condition in roughly equal proportions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/4\">",
"     4",
"    </a>",
"    ]. When associated with an identified etiology, NPH can occur in all age groups. In comparison, idiopathic NPH is most common in adults over the age of 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. It is equally common in both sexes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrospinal fluid (CSF) is produced by the choroid plexus in the lateral ventricles and flows from the lateral ventricles to the third and fourth ventricles and then through the basal cisterns, tentorium, and subarachnoid space over the cerebral convexities to the area of the sagittal sinus. CSF is absorbed into the systemic circulation primarily across the arachnoid villi into the venous channels of the sagittal sinus.",
"   </p>",
"   <p>",
"    Impaired absorption of CSF is the suspected mechanism in most cases of secondary normal pressure hydrocephalus (NPH). The most common identified underlying causes are intraventricular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subarachnoid hemorrhage (either from aneurysm or trauma) and prior acute or ongoing chronic meningitis (from infection, cancer, or inflammatory disease). Paget disease at the skull base, mucopolysaccharidosis of the meninges, and achondroplasia are other rarely reported causes of NPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These conditions are understood to cause inflammation and subsequent fibrosis of the arachnoid granulations, and thereby impair CSF resorption. Decreased CSF resorption leads to gradual accumulation of CSF within the ventricular system. While increased pressure is not measured on lumbar puncture, a pressure effect is nonetheless believed to occur locally on periventricular white matter tracts, producing the observed pathology and clinical symptoms.",
"   </p>",
"   <p>",
"    When no cause is identified, a previous head injury or subclinical viral meningeal infection may be considered. However, leptomeningeal biopsy in a series of 25 patients with idiopathic NPH revealed evidence of arachnoid fibrosis in about one-half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Other possible mechanisms have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The observation that larger head sizes are more common in patients with NPH than normal controls suggests the possibility that some patients with NPH have congenital hydrocephalus that becomes symptomatic later in life [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. Factors that theoretically could aggravate chronic hydrocephalus include systemic hypertension, recent head injury, sleep apnea, heart failure, and lung disease (the last three by raising jugular venous pressure and intracranial pressure).",
"     </li>",
"     <li>",
"      In two case series, a higher prevalence of systemic hypertension was found in patients with NPH compared with similarly-aged control groups with and without dementia [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Coronary, cerebrovascular, and peripheral arterial diseases were also more prevalent in patients with NPH [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/14\">",
"       14",
"      </a>",
"      ]. This association is somewhat corroborated by animal studies; as an example, one report showed that the spontaneously hypertensive rat develops hydrocephalus [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/16\">",
"       16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients with NPH also may have a higher than expected prevalence and severity of periventricular white matter disease on magnetic resonance imaging (MRI) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. These associations with hypertension and white matter disease have led some to propose that chronic periventricular ischemia leads to increased compliance of the ventricular wall and gradual ventricular enlargement due to normal fluctuations of intracranial pressure (ICP) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/17\">",
"       17",
"      </a>",
"      ]. Alternatively, periventricular ischemia may lead to locally increased venous resistance, which may lead to decreased CSF absorption and ventricular enlargement [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/19\">",
"       19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The evidence associating subcortical ischemia and NPH is somewhat conflicting. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'White matter lesions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      One ultrasound study in 20 patients with idiopathic NPH found that patients were more likely than controls (95 versus 25 percent) to have evidence of retrograde flow in the internal jugular veins during Valsalva [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/20\">",
"       20",
"      </a>",
"      ]. This finding suggests an underlying incompetence of the jugular valves, which, in theory, could lead to increased central venous pressure and impaired CSF absorption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal pressure hydrocephalus (NPH) is classically described as having three cardinal features [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gait difficulty",
"     </li>",
"     <li>",
"      Cognitive disturbance",
"     </li>",
"     <li>",
"      Urinary incontinence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These manifestations are believed to arise from dysfunction of periventricular white matter tracts, particularly those subserving frontal lobe connections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gait difficulty is the most prominent clinical feature in early stage NPH in most cases. It is also believed to be the most responsive feature to shunting. The gait abnormality is somewhat hard to characterize by both patients and clinicians; it is alternately described as a magnetic gait, gait apraxia, or a frontal ataxia. This reflects the appearance of the patient's feet being \"stuck\" to the floor. Steps are characteristically short, with decreased stride length and height, diminished cadence, and a broadened base with outwardly rotated feet [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Patients tend to turn slowly, with several steps. Postural stability is impaired, and a history of falls may be reported.",
"      <br/>",
"      <br/>",
"      The parkinsonian gait may bear a superficial resemblance to that of NPH but is distinguished by a narrow base and is more responsive to visual and acoustic cues [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/24\">",
"       24",
"      </a>",
"      ]. A computerized analysis of the gait of patients with NPH found an abnormal tendency toward cocontraction in antagonist muscle groups by electromyography, along with decreased rotation in the pelvis and counterrotation of the torso, indicating a deficit in subcortical motor control [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/23\">",
"       23",
"      </a>",
"      ]. Functional neuroimaging studies suggest a disturbance in the supplementary motor areas in the frontal lobe [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The cognitive disturbance of NPH has prominent subcortical and frontal features with psychomotor slowing, decreased attention and concentration, and apathy. Patients may appear depressed, but lack depressed thought content. Executive function, the ability to conceptualize all facets of an activity and translate that into appropriate and effective behavior, is impaired early in the course of NPH and may be more resistant to treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/25\">",
"       25",
"      </a>",
"      ]. Cortical features (aphasia, agnosia, apraxia) are less prominent.",
"      <br/>",
"      <br/>",
"      The Mini Mental State Examination may be an insensitive measure of cognitive impairment in NPH. Other cognitive measures and neuropsychological tests may aid in its characterization. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Neuropsychologic testing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Urinary urgency rather than incontinence may be present at early stages. Also, the patient's gait disorder may impede him from getting to the bathroom. In later stages, urinary incontinence is accompanied by a lack of concern, reflecting its probable origin in frontal lobe impairment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other features of NPH may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long tract signs with lower extremity spasticity, hyperreflexia, and extensor plantar responses",
"     </li>",
"     <li>",
"      Decreased coordination, hand tremor (usually postural rather than resting), and bradykinesia suggestive of parkinsonism",
"     </li>",
"     <li>",
"      Rigidity that is usually characterized by paratonia or Gegenhalten rather than the cogwheel rigidity of parkinsonism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link&amp;anchor=H58#H58\">",
"       \"The detailed neurologic examination in adults\", section on 'Muscle tone'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In late stages, frontal release signs, akinetic mutism, and quadriparesis may occur",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gait disorders are common in the elderly and include both neurologic and nonneurologic conditions, such as cervical or lumbosacral spondylosis, vestibular dysfunction, degenerative arthritis, visual impairment, and peripheral neuropathy. These may occur in isolation or in combination with other conditions that cause dementia.",
"   </p>",
"   <p>",
"    When cognitive impairment is prominent, the differential diagnosis of normal pressure hydrocephalus (NPH) should include other dementia syndromes, in particular those diseases that include prominent gait impairments early in the disease course, such as vascular dementia (VaD) and dementia with Lewy bodies (DLB). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VaD is more likely than NPH when a step-wise history of deterioration is reported, and when pseudobulbar palsy or long tract signs (Babinski sign, hyperreflexia, spasticity) are found on examination. Asymmetric findings are common in VaD but not in NPH.",
"      <br/>",
"      <br/>",
"      While early executive dysfunction is a common feature of both VaD and NPH, frontal lobe features (apathy, abulia) suggest NPH. Urinary incontinence is a less common symptom in VaD, but may be present from common comorbid conditions in the elderly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of vascular dementia\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Distinguishing NPH and the subcortical subtype of VaD is particularly difficult, as they share not only clinical features but also magnetic resonance imaging (MRI) features (see",
"      <a class=\"local\" href=\"#H10\">",
"       'White matter lesions'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/26\">",
"       26",
"      </a>",
"      ]. Some suggest that chronic subcortical ischemia may cause NPH as well as VaD (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      DLB and Parkinson disease dementia (PDD) are associated with gait abnormalities that bear at least superficial resemblance to that of NPH (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above). However, the cognitive dysfunction is usually distinctive in DLB and PDD with more prominent psychotic features, especially visual hallucinations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link\">",
"       \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15946?source=see_link\">",
"       \"Parkinson disease dementia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While Alzheimer disease (AD) itself does not impair gait early in its disease course, gait impairment from a variety of causes is common in older patients and may coexist with AD [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/27\">",
"       27",
"      </a>",
"      ]. Similarly, urinary incontinence from other causes (prostatism, stress incontinence) may coexist with AD: in one series, incontinence occurred in 12 percent of men and 36 percent of women over age 70 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/28\">",
"       28",
"      </a>",
"      ]. Prominent dementia, especially when it includes cortical features (aphasia, apraxia), strongly suggests AD as an alternative or comorbid diagnosis in a patient with suspected NPH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another potential problem is that NPH can coexist with other dementias, particularly AD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/3,9,29,30\">",
"     3,9,29,30",
"    </a>",
"    ]. In studies of patients with strong clinical and laboratory evidence of NPH, biopsies carried out at the time of shunting reveal AD pathology in 20 to 61 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/9,29-34\">",
"     9,29-34",
"    </a>",
"    ]. Two series have found that the degree of AD pathology correlated with the degree of cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. This suggests that AD should be considered as an alternative or contributory diagnosis when dementia is prominent. The coexistence of AD with NPH may have implications for the response to treatment. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Predictors of shunt efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic tests are required in the evaluation of patients with clinical evidence of normal pressure hydrocephalus (NPH) to exclude other conditions, to provide confirmation of the diagnosis, and to identify patients likely to respond to surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a patient with dementia first establishes the presence of cognitive impairment and provides a measure of its severity. Treatable conditions are excluded. In general, this evaluation includes a cognitive assessment (Mini-Mental State Examination or neuropsychological testing), and laboratory evaluations (vitamin B12 level and thyroid function tests). This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gold standard with which diagnostic tests for NPH are compared is a response to ventricular shunting. While this is appealing for pragmatic reasons, it is somewhat problematic in other ways. The definition of a positive response to shunting is not standardized, and there are factors other than misdiagnosis that can contribute to poor surgical response (eg, comorbid conditions, timing of surgery, complications of surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/35\">",
"     35",
"    </a>",
"    ]. Furthermore, positive predictive values are generally reported in these investigations; in small series, the influence of selection bias in the study population is likely to be both significant and difficult to characterize. This often limits the generalizability of the findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;While both MRI and computed tomography (CT) can evaluate ventricular and sulcal size, MRI is superior to CT in the evaluation of patients with possible NPH because it allows visualization of other markers of NPH, and provides additional information that can exclude other potential etiologies in the differential diagnosis. However, a CT scan can exclude NPH and is appropriate for screening purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ventriculomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark finding on CT or MRI is ventriculomegaly in the absence of, or out of proportion to, sulcal enlargement. Ventricular enlargement occurs normally with age as a result of progressive cortical atrophy; the rate of enlargement increases after the age of 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/36\">",
"     36",
"    </a>",
"    ]. In general, atrophy associated with age or neurodegenerative dementia produces a proportionate enlargement of both ventricular and sulcal size and is often called hydrocephalus ex vacuo (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76428 \" href=\"UTD.htm?24/2/24609\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Ventriculomegaly is considered to be present if the modified Evan's ratio is greater than 0.31 (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79460 \" href=\"UTD.htm?4/22/4450\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56382 \" href=\"UTD.htm?35/16/36098\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/37\">",
"     37",
"    </a>",
"    ]. This is calculated by measuring the maximal diameter of the frontal horns of the lateral ventricles (at the slice where the frontal horns are largest) to the maximum width of the cranial cavity measured at the inner tables of the skull at the same level.",
"   </p>",
"   <p>",
"    Prominent cortical atrophy, as manifested by diffuse sulcal enlargement, argues against the diagnosis of NPH and predicts a lesser likelihood of improvement with shunting (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76428 \" href=\"UTD.htm?24/2/24609\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In one series, for example, a measurement of the largest sulcus in the frontal or parietal region of less than 1.9 mm was associated with universal improvement with shunting (in all 17 patients), while sulci &ge;5 mm was associated with less certain improvement (15 of 27) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/40\">",
"     40",
"    </a>",
"    ]. Others have also found that sulcal enlargement does not exclude the possibility of improvement with shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/8\">",
"     8",
"    </a>",
"    ]. A population-based study of 858 older individuals correlated a measure of disproportionate dilation of ventricular versus sulcal CSF space on MRI with gait and cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/41\">",
"     41",
"    </a>",
"    ]. However, this study did not assess a diagnosis of NPH in these individuals nor a response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     White matter lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with NPH, MRI may show a characteristic high signal abnormality around the ventricles, which is thought to represent transependymal egress of fluid. It is difficult, however, to distinguish this finding from the ubiquitous white matter changes in the elderly or from that representing subcortical vascular dementia. The extent of white matter disease may correlate with the degree of cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=see_link&amp;anchor=H16#H16\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\", section on 'White matter lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between white matter lesions and the response to shunting has been variable. Most studies have found that the more extensive the white matter lesions, the less likely and significant the improvement after shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/4,42,43\">",
"     4,42,43",
"    </a>",
"    ]. However, there are studies showing a good response to shunting in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/26,39,40\">",
"     26,39,40",
"    </a>",
"    ] or no correlation with outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/5,17,44\">",
"     5,17,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear whether the usually poor response to shunting means that extensive white matter disease represents a late stage of NPH no longer amenable to treatment or an alternative pathophysiology (subcortical vascular dementia). In at least two series, there was evidence of reduction of periventricular white matter lesions around the frontal lobes after surgery in patients who improved compared with those who did not, suggesting that the observed white matter changes may, at least in part, represent a reversible, secondary phenomenon of NPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/26,44\">",
"     26,44",
"    </a>",
"    ]. It is also possible that white matter lesions do not cause NPH but that they commonly coexist [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study suggests that diffusion-weighted imaging (DWI) may help distinguish between chronic ischemic changes and the white matter changes associated with NPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/45\">",
"     45",
"    </a>",
"    ]. Increased diffusivity is noted in the former condition, while patients with NPH had similar diffusivity compared with controls. Further studies are needed to confirm this finding and associate it with surgical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Aqueduct flow void",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI in patients with NPH frequently demonstrates loss of signal in the aqueduct of Sylvius, a finding that has been called aqueduct flow void and is thought to represent higher than normal flow velocity of cerebrospinal fluid (CSF) in the aqueduct (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71397 \" href=\"UTD.htm?39/47/40690\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An initial retrospective study of 20 patients suggested that the anatomic extent of flow void in the cerebral aqueduct correlated with the initial surgical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/46\">",
"     46",
"    </a>",
"    ]. However, subsequent studies found no difference between the extent of flow void in patients with idiopathic NPH compared with age-matched controls, and a poor correlation with postoperative outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/18,47,48\">",
"     18,47,48",
"    </a>",
"    ]. Postoperative clinical improvement is not associated with resolution of this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/44,46\">",
"     44,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other findings on MRI may provide evidence of a diagnosis other than NPH that explains or contributes to the patient's clinical syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRI permits better visualization of the posterior fossa than CT, possibly detecting aqueductal stenosis or a Chiari malformation that may cause obstructive hydrocephalus.",
"     </li>",
"     <li>",
"      MRI allows volumetric assessment of medial temporal lobe structures, which may be important because medial temporal atrophy suggests the diagnosis of AD [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/49\">",
"       49",
"      </a>",
"      ]. In two series, medial temporal atrophy, as manifested by either more dilated perihippocampal fissures or as a lower hippocampal volume, was significantly greater in patients with AD compared with NPH [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. Among patients with NPH, one series found a nonsignificant trend between higher hippocampal volumes (ie, less temporal atrophy) and benefit from shunting [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MRI is sensitive for the diagnosis of cerebrovascular disease; however, the distinction between transependymal fluid flow and subcortical white matter ischemia is difficult.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neuropsychologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;No single finding or combination of findings on neuropsychological testing is particularly sensitive or specific for NPH nor predicts a response to shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/7\">",
"     7",
"    </a>",
"    ]. However, a neuropsychological assessment may provide useful information in the evaluation of patients with NPH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It provides a baseline measurement for future comparison, especially after a diagnostic or surgical procedure. The Mini Mental State Examination may be an insensitive measure of cognitive impairment in NPH.",
"     </li>",
"     <li>",
"      The characteristic pattern in NPH is that of \"frontal-subcortical\" dysfunction, in which the patient is slower in timed tasks, performs poorly on tests of divided attention and executive function, has difficulty with fluency tests, and has poor learning and better preserved recognition memory [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/25,52\">",
"       25,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It may aid in the diagnosis of comorbid disease (eg, Alzheimer disease and other causes of dementia). Cortical features (eg, aphasia, apraxia) are atypical for NPH, particularly early in the disease course.",
"     </li>",
"     <li>",
"      It may also aid in prognosis. The presence of anomia, in particular, has been associated with a lesser benefit from surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/53,54\">",
"       53,54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Confirmatory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the invasive nature of the treatment for NPH, and a substantial failure rate, it is generally recommended that additional tests be performed that provide some measure of the patient's likelihood of responding to surgery. These vary considerably in their invasiveness and requirements for hospitalization and technical expertise, and none have clearly defined sensitivity or specificity. We use the lumbar tap test, a simple, outpatient procedure, to select patients for surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Removal of CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests measuring a clinical response to removal of cerebrospinal fluid (CSF) are appealing since they appear to simulate a response to shunting. Such tests have gained the most acceptance in the diagnosis of NPH and selection of patients for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/1,35\">",
"     1,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lumbar tap test &mdash; The simplest test can be done as an office procedure. Using lumbar puncture, 30 to 50 ml of CSF is removed with documentation of the patient's gait and cognitive function before and 30 to 60 minutes after the procedure. This is sometimes called the Fisher test. Common parameters measured before and after CSF removal include measures of gait speed, stride length, reaction time, and tests of verbal memory and visual attention [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/55\">",
"       55",
"      </a>",
"      ]. We find it useful to make a videotape of the gait before and after the tap. In addition to recording these measures in the office, it is useful to get feedback from the patient and family regarding any subjective improvement over the next few days.",
"      <br/>",
"      <br/>",
"      Documented improvement in one or more of these measures following the procedure suggests that the patient will have a better outcome after placement of a ventriculoperitoneal shunt [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/56\">",
"       56",
"      </a>",
"      ]. Most studies suggest that this test has excellent positive predictive value (90 to 100 percent), but limited negative predictive value (30 to 50 percent), with a number of patients who show no response to removal of CSF but later improve with surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/8,57,58\">",
"       8,57,58",
"      </a>",
"      ]. Others report that this test does not add predictive value over clinical and radiographic criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lumbar drainage &mdash; An alternative method involves continuous CSF drainage at a rate of 5 to 10",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      via a temporary catheter in the lumbar CSF space. Clinicians, patients, and family members evaluate the clinical response over an observation period in hospital of two to seven days. Clinical improvement after CSF drainage is not associated with change in ventricular size; hence neuroimaging is not a routine part of this assessment [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/60\">",
"       60",
"      </a>",
"      ]. In small series (&lt;20 patients), this technique has reportedly had 100 percent sensitivity and specificity in predicting subsequent response to shunting [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, others report that, while correctly identifying shunt responders, the negative predictive value is low [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/63\">",
"       63",
"      </a>",
"      ]. In one series, for example, 38 patients with a negative response to lumbar tap underwent lumbar drainage, with an 87 percent positive predictive value for surgical response [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/57\">",
"       57",
"      </a>",
"      ]. However, 63 percent of patients with a negative response improved after shunting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings (high positive predictive value, variable negative predictive value) were noted in a small study that evaluated direct removal of CSF from the ventricles [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meningitis and subdural hematoma are serious complications of these tests, particularly prolonged lumbar drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/7,57\">",
"     7,57",
"    </a>",
"    ]. These are in general rare, but occurred in 2 of 38 patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is reasonable to send routine diagnostic tests (cell count, protein, glucose) on the CSF when a lumbar puncture is performed in this setting. In most cases of idiopathic NPH, it is expected that these test results will be normal, although a mild elevation of protein in isolation is a common nonspecific finding. Pleocytosis requires a rigorous evaluation to determine the underlying etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4424?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the patient with chronic meningitis\", section on 'CSF examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Intracranial pressure monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged pressure monitoring via an intracranial transducer in patients with NPH reveals intermittent rhythmic pressure deviations or Lundberg B waves (0.5 to 2 per minute oscillations). Some clinicians use measures of basal ICP greater than 5 to 10 mm Hg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence or predominance of B-waves to diagnosis NPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, B-waves occurring during more than 50 percent of the recording time has been associated with a good response to shunting in some studies, but in others appeared only weakly associated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/4,6,53,65-67\">",
"     4,6,53,65-67",
"    </a>",
"    ]. The invasive nature of this technique and lack of normative criteria limit its use in the evaluation of patients with NPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/1,68\">",
"     1,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     CSF infusion tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of techniques to evaluate CSF dynamics have been studied in the evaluation of patients with NPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/40\">",
"     40",
"    </a>",
"    ]. One of the simpler methods involves the insertion of two lumbar cannulas, one for pressure monitoring, the other for infusion of normal saline, lactated Ringer's solution, or artificial CSF into the CSF space [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/31,40,58,69-71\">",
"     31,40,58,69-71",
"    </a>",
"    ]. At a constant infusion rate (1.6 to 2.0",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    CSF pressure is measured at a plateau or steady state and represents that pressure at which CSF absorption and infusion are balanced. A threshold level of high pressure identifies individuals likely to have shunt responsive NPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, the resistance to CSF outflow (Rcsf) is calculated as the difference between the steady state pressure during infusion and the baseline pressure, divided by the infusion rate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/70\">",
"     70",
"    </a>",
"    ]. Rcsf values between 12 and 18",
"    <span class=\"nowrap\">",
"     mmHg/mL",
"    </span>",
"    per minute are commonly used thresholds to identify patients who might benefit from shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. In one series of 40 normal older adults (60 to 82 years), the 90",
"    <sup>",
"     th",
"    </sup>",
"    percentile for Rcsf was 17.4",
"    <span class=\"nowrap\">",
"     mmHg/mL",
"    </span>",
"    per minute; 25 percent were above 12",
"    <span class=\"nowrap\">",
"     mmHg/mL",
"    </span>",
"    per minute and 10 percent were above 18",
"    <span class=\"nowrap\">",
"     mmHg/mL,",
"    </span>",
"    indicating that an important pitfall for this test that high Rcsf may be found in persons without NPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/72\">",
"     72",
"    </a>",
"    ]. Other techniques make use of bolus injections, providing an additional measure of ventricular compliance,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    computerized analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This test appears to be more specific than sensitive. In the multicenter Dutch Normal Pressure Hydrocephalus study, 95 patients with suspected NPH based on clinical symptoms and CT criteria, underwent a preoperative infusion test; all had a shunt placed regardless of the results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/70\">",
"     70",
"    </a>",
"    ]. An Rcsf of &ge;18",
"    <span class=\"nowrap\">",
"     mmHg/mL",
"    </span>",
"    per minute was associated with a sensitivity and specificity for shunt responsiveness of 46 and 87 percent, respectively.",
"   </p>",
"   <p>",
"    In studies comparing this test with high volume lumbar tap, results agree 45 to 72 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/7,58\">",
"     7,58",
"    </a>",
"    ]. In one of these series, the lumbar tap test had a higher positive predictive value (94 percent) compared with the infusion test (80 percent); however, false negative predictions also appeared higher with the lumbar tap test (58 versus 16 percent). Others have reported that CSF infusion tests added no predictive ability for shunt response over other diagnostic criteria and neuroimaging [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/31,59\">",
"     31,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This test may also provide a useful measure of shunt functioning after surgery, as one study of 32 patients followed for three years after receiving a shunt for idiopathic NPH found that Rcsf decreased postoperatively and remained decreased, and thereby provided a useful measure of shunt functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While this technique appears to have clinical utility in the above reports, it is invasive, poorly standardized, somewhat uncomfortable for at least some patients, and requires technical expertise, which appears to be limited to relatively few institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/1,35\">",
"     1,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cisternography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isotope cisternography consists of injection of a radiolabeled isotope into the lumbar cistern and visualizing its distribution through the cisterns, ventricles, and brain convexities at set time periods following its introduction (4, 24, 48, and 72 hours). NPH is suggested by nonappearance of the isotope over the brain convexities at 72 hours.",
"   </p>",
"   <p>",
"    While still often performed in the evaluation of patients with NPH, the utility of this test is limited with poor predictive values for surgical response [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/1,4,8,35,38,74\">",
"     1,4,8,35,38,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CSF biomarkers have been studied in small series of patients with NPH, showing elevated levels of tau, neurofilament triplet protein, and sulfatide levels as well as decreased levels of beta-amyloid peptide 1-42 compared with controls with Alzheimer disease, vascular dementia, or asymptomatic adults [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/75-78\">",
"       75-78",
"      </a>",
"      ]. While such studies are not routinely performed in the evaluation of dementia, a pattern of CSF biomarkers that suggests AD should cast doubt on the diagnosis of NPH and suggests that the patient will likely to continue to decline, despite shunting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=see_link&amp;anchor=H26#H26\">",
"       \"Clinical manifestations and diagnosis of Alzheimer disease\", section on 'Other laboratory testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other MRI techniques such as cine-MRI and perfusion-weighted MRI have had either mixed or negative results in the evaluation of patients with NPH [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/48,79,80\">",
"       48,79,80",
"      </a>",
"      ]. A small pilot study of magnetic resonance spectroscopy has shown findings in NPH that appear to correlate with cognitive deterioration [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Single photon emission CT (SPECT) studies have shown decreased cerebral blood flow in the frontal and periventricular areas in patients with NPH [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/53,82,83\">",
"       53,82,83",
"      </a>",
"      ]. Regional decreases in cerebral metabolism have also been shown on positron emission tomography (PET) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/84\">",
"       84",
"      </a>",
"      ]. However, these tests do not clearly predict shunt responsiveness, and a clinical role for these studies in NPH has not been established [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/4,35\">",
"       4,35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for normal pressure hydrocephalus (NPH) is ventricular shunting. Medical therapies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    or osmotic diuretics have not been shown to be effective. Similarly, although repeated high-volume taps have been proposed as an alternative to surgery, there are no published data that provide evidence of efficacy of this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Efficacy of shunting",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of shunting in NPH reported that 59 percent of patients improved after surgery on at least one measure of gait, cognition, or disability [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/8\">",
"     8",
"    </a>",
"    ]. Despite this analysis, the data supporting the efficacy of shunting is quite limited for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Case series are generally small (often just 20 to 30 patients), with short follow-up times, and are universally uncontrolled.",
"     </li>",
"     <li>",
"      Studies vary substantially in the diagnostic and clinical criteria used to select patients for surgery. These criteria impact outcome.",
"     </li>",
"     <li>",
"      The reports use a variety of postoperative assessment measures. While objective tools to measure cognitive and gait deficits in NPH have been reported, they are not validated or widely used [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/53,70\">",
"       53,70",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gait impairment is cited as the symptom that is most responsive to shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/3,4,31,85\">",
"     3,4,31,85",
"    </a>",
"    ]. However, because outcome measures vary so widely between studies, it is difficult to estimate a general response rate.",
"   </p>",
"   <p>",
"    Cognitive impairment, while more resistant to treatment, may improve with surgery, especially if not severe at the time of intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/8,25,31,39,85\">",
"     8,25,31,39,85",
"    </a>",
"    ]. The percentage of patients reported to show cognitive improvement following surgery varies from 0 to 84 percent and depends upon several factors, including the outcome measure used [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/3,38,63,85-88\">",
"     3,38,63,85-88",
"    </a>",
"    ]. In one study of eleven patients examined with standardized neuropsychological tests, cognition improved in both demented and nondemented individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/25\">",
"     25",
"    </a>",
"    ]. However, significant deficits, particularly those of frontal and executive function, remained in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/25\">",
"     25",
"    </a>",
"    ]. Another study reported that improvement in reaction time accounted for 52 percent of the improved cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/8,39\">",
"     8,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urinary incontinence improves in 36 to 90 percent of patients even though it is a late symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/3,8,31,42,85,88\">",
"     3,8,31,42,85,88",
"    </a>",
"    ]. Complete resolution is less common, occurring in one report in 4 of 23 patients at one year after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It seems plausible that surgical intervention might prevent progression of neurologic deficits, but the lack of control groups in the available reports preclude this conclusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Predictors of shunt efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors have been associated with the response to shunting (",
"    <a class=\"graphic graphic_table graphicRef80958 \" href=\"UTD.htm?38/61/39899\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/5,6,53,54,89\">",
"     5,6,53,54,89",
"    </a>",
"    ]. The absence of any one favorable predictor or the presence of a negative predictor does not rule out the possibility of a shunt response. The predictive values of diagnostic test findings are discussed above (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Diagnostic tests'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The following factors are among those proposed to affect the response to surgery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dementia &mdash; Patients with moderate to severe dementia are unlikely to improve after shunting [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/8\">",
"       8",
"      </a>",
"      ]. This may reflect progression of NPH to an advanced stage in which neurologic injury is fixed or that an underlying degenerative dementia such as Alzheimer disease (AD) is the cause or contributor to the patient's syndrome (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Differential diagnosis'",
"      </a>",
"      above).",
"      <br/>",
"      <br/>",
"      In two case series that included a cortical biopsy, AD pathology was associated with limited or absent postoperative improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. In comparison, others have suggested that AD pathology is not associated with a poor surgical response, but these studies had a follow-up period of only a few months [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/10,30\">",
"       10,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cause of NPH &mdash; Patients with idiopathic NPH have lower rates of improvement after shunt placement compared with patients with a known etiology [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/4,8,39,74\">",
"       4,8,39,74",
"      </a>",
"      ]. In one of the largest reported series, marked improvement after surgery occurred in 15 percent of the idiopathic group compared with 36 percent of the patients with secondary NPH [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Duration of symptoms &mdash; Data regarding the preoperative duration of symptoms reveal the strongest association with outcome at the extremes of symptom duration; patients with less than six-month duration have the highest chance of improvement, while those with symptoms, particularly dementia, present for more than two or three years have lower rates of improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/5,7,53,89\">",
"       5,7,53,89",
"      </a>",
"      ]. In one series, dementia present for more than two years was associated with shunt failure in five of seven patients, while 21 of 23 patients with a shorter duration of symptoms improved after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/53\">",
"       53",
"      </a>",
"      ]. However, others have not found an association between duration of symptoms and surgical response [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/8,70\">",
"       8,70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age &mdash; Most studies do not find that age influences surgical outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/4\">",
"       4",
"      </a>",
"      ]. However, selection bias may influence these results. In one series, advanced age predicted a worse response to temporary lumbar drainage [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/7\">",
"       7",
"      </a>",
"      ]. However, among the 84 patients with a positive response to lumbar drainage who went on to surgery, age did not influence surgical response.",
"     </li>",
"     <li>",
"      Clinical manifestations &mdash; The relative prominence of the gait disorder versus cognitive impairment, especially early in the course of the syndrome, is felt by many to be associated with surgical outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/8,53,89\">",
"       8,53,89",
"      </a>",
"      ]. Late presenting or no gait disorder predicts a poor surgical outcome in more than 80 percent of patients, while early gait disorder was less strongly predictive of surgical success, in 40 to 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/8,38,90\">",
"       8,38,90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Urinary incontinence &mdash; Despite the fact that urinary incontinence is a late sign of NPH, its presence does not clearly impact on a patient's chance of improvement after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/5,8\">",
"       5,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Types of shunts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most shunts divert cerebrospinal fluid (CSF) from a catheter in the lateral ventricle into the abdomen (ventriculoperitoneal) or less commonly into the heart (ventriculoatrial). Lumboperitoneal shunts are uncommonly described.",
"   </p>",
"   <p>",
"    CSF flow is controlled via a one-way valve; many different models are in clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Shunts are often classified into low, medium, and high pressure systems. A programmable valve has been developed that allows pressure adjustments without reoperation. In the setting of subdural hematoma, an increase in the pressure setting can aid in hematoma resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/35\">",
"     35",
"    </a>",
"    ]. In patients without a clinical response to shunt placement, the pressure setting can be lowered to increase drainage.",
"   </p>",
"   <p>",
"    Studies comparing efficacy and complications of different shunts are limited. These are unblinded comparisons, and mostly retrospective:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective comparison of programmable versus standard shunt valves among 407 patients with NPH found a higher incidence of nontraumatic subdural hematoma and hygromas for the programmable valve versus the standard valve (8.5 versus 3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/92\">",
"       92",
"      </a>",
"      ]. However, there was no significant difference in the number of surgical decompressions or the number of subsequent surgical shunt revisions (25 versus 23 percent). The cost of implanting a programmable valve was estimated to be three times as much as the standard valve.",
"     </li>",
"     <li>",
"      The Dutch NPH trial randomly assigned 96 patients with NPH to receive either a low (40 mm H2O) or medium-high (100 mm H2O) pressure shunt [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/93\">",
"       93",
"      </a>",
"      ]. There was a strong trend toward a higher rate of improvement on a combined measure of gait and cognition in patients receiving a low pressure shunt (74 versus 53 percent with a medium pressure shunt, p = 0.06). Subdural effusions were more common in the low pressure shunt group (71 versus 34 percent), but these did not affect clinical outcome. Unblinded outcome assessments limit the ability to draw firm conclusions from this study.",
"     </li>",
"     <li>",
"      A retrospective comparison of a flow-regulated shunt system with the more traditional pressure regulated system found no differences in complication rate, shunt malfunctions, or operative success [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Shunt complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of studies of shunting in NPH reported a pooled mean shunt complication rate of 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/8\">",
"     8",
"    </a>",
"    ]. Six percent of patients had complications resulting in permanent neurologic sequelae or death and 22 percent required a second surgery. A subsequently published case series that was relatively large (55 patients) reported that 53 percent of their patients required a shunt revision over 6 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other reported complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subdural effusion",
"     </li>",
"     <li>",
"      Subdural hematoma",
"     </li>",
"     <li>",
"      Intracranial infection",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Intracerebral hemorrhage from catheter placement",
"     </li>",
"     <li>",
"      Mechanical shunt failures or blocked shunts",
"     </li>",
"     <li>",
"      Abdominal injury (ascites, peritonitis, abdominal perforations, volvulus) in ventriculoperitoneal shunts",
"     </li>",
"     <li>",
"      Arrhythmias from incorrect distal catheter placement, systemic emboli in ventriculoatrial shunts",
"     </li>",
"     <li>",
"      Intracerebral hemorrhage is an immediate surgical complication, occurring in 3 to 6 percent of cases.",
"     </li>",
"     <li>",
"      Subdural effusion and hematoma are the most common complications in the first year, occurring in 2 to 17 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/8\">",
"       8",
"      </a>",
"      ]. Higher rates are seen when routine postoperative computed tomography (CT) scans are performed [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/93\">",
"       93",
"      </a>",
"      ]. In most cases, this is thought to result from tearing of bridging veins in the setting of shunt overdrainage. Surgical evacuation is required in a minority of these patients.",
"     </li>",
"     <li>",
"      Shunt infections usually present within the first month after operation (or reoperation), but can appear later [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/85\">",
"       85",
"      </a>",
"      ]. The manifestations may be quite vague with varying degrees of headache, malaise, nausea, vomiting, and fever. The most common pathogens arise from skin flora.",
"      <br/>",
"      <br/>",
"      Direct aspiration of CSF from the shunt is often required for diagnosis. Removal of the shunt as well as antibiotic treatment is usually recommended. This topic is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=see_link\">",
"       \"Infections of central nervous system shunts and other devices\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Shunt malfunction or suboptimal function may be to blame if a patient fails to improve after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/4\">",
"       4",
"      </a>",
"      ]. If a programmable valve was placed, lowering the pressure setting to improve drainage may be indicated. Otherwise, lumbar tap tests and CSF infusion tests may be used to determine if shunt revision should be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While most shunt complications have the highest incidence within the first year, shunt malfunction is an enduring risk [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/85,95\">",
"     85,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The routine performance of a brain CT in follow-up is of undetermined clinical utility. While ventricular size may decrease postoperatively, studies have mixed results in associating this with postoperative improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/31\">",
"     31",
"    </a>",
"    ]. Thus, CT scan cannot be considered a reliable indicator of shunt functioning. CT scan may also detect a subclinical subdural effusion or hematoma, but as these are unlikely to require treatment, the utility of diagnosing them is uncertain.",
"   </p>",
"   <p>",
"    Regular follow-up and attention to symptoms is required. When patients experience neurologic deterioration, a brain CT scan should be performed to exclude the possibility of subdural hematoma and check the catheter position. A shunt series of a plain x-ray films that visualize the entire shunt system should be performed, looking for visible obstruction. An abdominal ultrasound may also detect obstruction of the shunt tip.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few published data on longer term follow-up after shunting in patients with normal pressure hydrocephalus (NPH), and no natural history data.",
"   </p>",
"   <p>",
"    The literature is conflicting as to how often initial improvement is sustained. In most series that have one year or more follow-up after surgery, sustained improvement is seen in only one-half of those who initially improve [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/3,8,73,74,96,97\">",
"     3,8,73,74,96,97",
"    </a>",
"    ]. In contrast, in the Dutch NPH trial, most patients experiencing an improvement did so within the first month and remained stable at one year; only a minority had initial improvement that was followed by decline [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/93\">",
"     93",
"    </a>",
"    ]. In another report, one-third of their patients experienced a more gradual recovery at up to 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/5\">",
"     5",
"    </a>",
"    ]. Finally, a relatively large case series from Baltimore (55 patients) reported that more than 60 percent maintained clinical improvement over six years of follow-up, although a substantial number required multiple shunt revisions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality appears increased in patients with NPH compared with the general elderly population, but is similar to age and sex-matched patients with stroke, perhaps reflecting shared risk factors or etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?14/26/14762/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal pressure hydrocephalus (NPH) refers to a condition of pathologically enlarged ventricular size with normal opening pressures on lumbar puncture.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary NPH is most commonly associated with subarachnoid hemorrhage or meningitis, occurs in any age group, and is associated with impaired cerebrospinal fluid (CSF) resorption. Idiopathic NPH is more common and occurs in elderly individuals. Its pathogenesis is uncertain. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NPH is associated with a classic triad of cognitive impairment, gait disturbance, and urinary incontinence. Shunt responsive NPH is more likely when the gait disturbance appears early on and is more prominent than the cognitive impairment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The brain magnetic resonance imaging (MRI) is an essential test in a patient with NPH and demonstrates ventriculomegaly out of proportion to sulcal enlargement and no evidence of CSF flow obstruction. Extensive white matter disease and cortical atrophy, particularly involving the medial temporal lobe, are unfavorable indicators for shunt responsive NPH. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with clinical and MRI features suggestive of NPH, we use a lumbar tap test to identify patients likely to respond to shunt placement (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Removal of CSF'",
"      </a>",
"      above). Other confirmatory tests available in experienced centers include intracranial pressure monitoring, lumbar drain, and CSF infusion tests. The sensitivity and specificity of these tests are uncertain. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest ventricular shunting in patients who have clinical and MRI evidence of NPH, a positive test result associated with response to shunting (eg, lumbar tap test), and limited or absent negative prognostic indicators (",
"      <a class=\"graphic graphic_table graphicRef80958 \" href=\"UTD.htm?38/61/39899\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Predictors of shunt efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In selected populations, up to two-thirds of patients can expect some degree of benefit after shunting. In half of these, however, the benefit will not be sustained. Some prognostic indicators may identify those more or less likely to achieve benefit (",
"      <a class=\"graphic graphic_table graphicRef80958 \" href=\"UTD.htm?38/61/39899\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Efficacy of shunting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Shunt complications are common and potentially severe, even fatal, and require vigilance in follow-up on the part of patients and families. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/1\">",
"      Krauss JK, Halve B. Normal pressure hydrocephalus: survey on contemporary diagnostic algorithms and therapeutic decision-making in clinical practice. Acta Neurochir (Wien) 2004; 146:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/2\">",
"      Tisell M, H&ouml;glund M, Wikkels&oslash; C. National and regional incidence of surgery for adult hydrocephalus in Sweden. Acta Neurol Scand 2005; 112:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/3\">",
"      Klassen BT, Ahlskog JE. Normal pressure hydrocephalus: how often does the diagnosis hold water? Neurology 2011; 77:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/4\">",
"      Vanneste JA. Diagnosis and management of normal-pressure hydrocephalus. J Neurol 2000; 247:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/5\">",
"      Petersen RC, Mokri B, Laws ER Jr. Surgical treatment of idiopathic hydrocephalus in elderly patients. Neurology 1985; 35:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/6\">",
"      Black PM, Ojemann RG, Tzouras A. CSF shunts for dementia, incontinence, and gait disturbance. Clin Neurosurg 1985; 32:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/7\">",
"      Marmarou A, Young HF, Aygok GA, et al. Diagnosis and management of idiopathic normal-pressure hydrocephalus: a prospective study in 151 patients. J Neurosurg 2005; 102:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/8\">",
"      Hebb AO, Cusimano MD. Idiopathic normal pressure hydrocephalus: a systematic review of diagnosis and outcome. Neurosurgery 2001; 49:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/9\">",
"      Bech RA, Juhler M, Waldemar G, et al. Frontal brain and leptomeningeal biopsy specimens correlated with cerebrospinal fluid outflow resistance and B-wave activity in patients suspected of normal-pressure hydrocephalus. Neurosurgery 1997; 40:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/10\">",
"      Bech RA, Waldemar G, Gjerris F, et al. Shunting effects in patients with idiopathic normal pressure hydrocephalus; correlation with cerebral and leptomeningeal biopsy findings. Acta Neurochir (Wien) 1999; 141:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/11\">",
"      Graff-Radford NR, Godersky JC. Symptomatic congenital hydrocephalus in the elderly simulating normal pressure hydrocephalus. Neurology 1989; 39:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/12\">",
"      Krefft TA, Graff-Radford NR, Lucas JA, Mortimer JA. Normal pressure hydrocephalus and large head size. Alzheimer Dis Assoc Disord 2004; 18:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/13\">",
"      McComb JG, Bradley WG Jr, Safar FG, et al. Is a large hat size hazardous to your health? AJNR Am J Neuroradiol 2004; 25:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/14\">",
"      Krauss JK, Regel JP, Vach W, et al. Vascular risk factors and arteriosclerotic disease in idiopathic normal-pressure hydrocephalus of the elderly. Stroke 1996; 27:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/15\">",
"      Graff-Radford NR, Godersky JC. Idiopathic normal pressure hydrocephalus and systemic hypertension. Neurology 1987; 37:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/16\">",
"      Ritter S, Dinh TT. Progressive postnatal dilation of brain ventricles in spontaneously hypertensive rats. Brain Res 1986; 370:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/17\">",
"      Bradley WG Jr, Whittemore AR, Watanabe AS, et al. Association of deep white matter infarction with chronic communicating hydrocephalus: implications regarding the possible origin of normal-pressure hydrocephalus. AJNR Am J Neuroradiol 1991; 12:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/18\">",
"      Krauss JK, Regel JP, Vach W, et al. White matter lesions in patients with idiopathic normal pressure hydrocephalus and in an age-matched control group: a comparative study. Neurosurgery 1997; 40:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/19\">",
"      Bradley WG. Normal pressure hydrocephalus: new concepts on etiology and diagnosis. AJNR Am J Neuroradiol 2000; 21:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/20\">",
"      Kuriyama N, Tokuda T, Miyamoto J, et al. Retrograde jugular flow associated with idiopathic normal pressure hydrocephalus. Ann Neurol 2008; 64:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/21\">",
"      ADAMS RD, FISHER CM, HAKIM S, et al. SYMPTOMATIC OCCULT HYDROCEPHALUS WITH \"NORMAL\" CEREBROSPINAL-FLUID PRESSURE.A TREATABLE SYNDROME. N Engl J Med 1965; 273:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/22\">",
"      Lenfeldt N, Larsson A, Nyberg L, et al. Idiopathic normal pressure hydrocephalus: increased supplementary motor activity accounts for improvement after CSF drainage. Brain 2008; 131:2904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/23\">",
"      Sudarsky L, Simon S. Gait disorder in late-life hydrocephalus. Arch Neurol 1987; 44:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/24\">",
"      Stolze H, Kuhtz-Buschbeck JP, Dr&uuml;cke H, et al. Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/25\">",
"      Iddon JL, Pickard JD, Cross JJ, et al. Specific patterns of cognitive impairment in patients with idiopathic normal pressure hydrocephalus and Alzheimer's disease: a pilot study. J Neurol Neurosurg Psychiatry 1999; 67:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/26\">",
"      Tullberg M, Hultin L, Ekholm S, et al. White matter changes in normal pressure hydrocephalus and Binswanger disease: specificity, predictive value and correlations to axonal degeneration and demyelination. Acta Neurol Scand 2002; 105:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/27\">",
"      Sudarsky L, Ronthal M. Gait disorders among elderly patients. A survey study of 50 patients. Arch Neurol 1983; 40:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/28\">",
"      Temml C, Haidinger G, Schmidbauer J, et al. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn 2000; 19:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/29\">",
"      Savolainen S, Palj&auml;rvi L, Vapalahti M. Prevalence of Alzheimer's disease in patients investigated for presumed normal pressure hydrocephalus: a clinical and neuropathological study. Acta Neurochir (Wien) 1999; 141:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/30\">",
"      Golomb J, Wisoff J, Miller DC, et al. Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry 2000; 68:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/31\">",
"      Savolainen S, Hurskainen H, Palj&auml;rvi L, et al. Five-year outcome of normal pressure hydrocephalus with or without a shunt: predictive value of the clinical signs, neuropsychological evaluation and infusion test. Acta Neurochir (Wien) 2002; 144:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/32\">",
"      Hamilton R, Patel S, Lee EB, et al. Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol 2010; 68:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/33\">",
"      Leinonen V, Koivisto AM, Savolainen S, et al. Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Ann Neurol 2010; 68:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/34\">",
"      Pyykk&ouml; OT, Helisalmi S, Koivisto AM, et al. APOE4 predicts amyloid-&beta; in cortical brain biopsy but not idiopathic normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 2012; 83:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/35\">",
"      Malm J, Eklund A. Idiopathic normal pressure hydrocephalus. Practical Neurology 2006; 6:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/36\">",
"      Barron SA, Jacobs L, Kinkel WR. Changes in size of normal lateral ventricles during aging determined by computerized tomography. Neurology 1976; 26:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/37\">",
"      Gyldensted C. Measurements of the normal ventricular system and hemispheric sulci of 100 adults with computed tomography. Neuroradiology 1977; 14:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/38\">",
"      Black PM. Idiopathic normal-pressure hydrocephalus. Results of shunting in 62 patients. J Neurosurg 1980; 52:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/39\">",
"      Thomsen AM, B&oslash;rgesen SE, Bruhn P, Gjerris F. Prognosis of dementia in normal-pressure hydrocephalus after a shunt operation. Ann Neurol 1986; 20:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/40\">",
"      B&oslash;rgesen SE, Gjerris F. The predictive value of conductance to outflow of CSF in normal pressure hydrocephalus. Brain 1982; 105:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/41\">",
"      Palm WM, Saczynski JS, van der Grond J, et al. Ventricular dilation: association with gait and cognition. Ann Neurol 2009; 66:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/42\">",
"      Krauss JK, Droste DW, Vach W, et al. Cerebrospinal fluid shunting in idiopathic normal-pressure hydrocephalus of the elderly: effect of periventricular and deep white matter lesions. Neurosurgery 1996; 39:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/43\">",
"      Boon AJ, Tans JT, Delwel EJ, et al. Dutch Normal-Pressure Hydrocephalus Study: the role of cerebrovascular disease. J Neurosurg 1999; 90:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/44\">",
"      Tullberg M, Jensen C, Ekholm S, Wikkels&oslash; C. Normal pressure hydrocephalus: vascular white matter changes on MR images must not exclude patients from shunt surgery. AJNR Am J Neuroradiol 2001; 22:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/45\">",
"      Tullberg M, Ziegelitz D, Ribbelin S, Ekholm S. White matter diffusion is higher in Binswanger disease than in idiopathic normal pressure hydrocephalus. Acta Neurol Scand 2009; 120:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/46\">",
"      Bradley WG Jr, Whittemore AR, Kortman KE, et al. Marked cerebrospinal fluid void: indicator of successful shunt in patients with suspected normal-pressure hydrocephalus. Radiology 1991; 178:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/47\">",
"      Krauss JK, Regel JP, Vach W, et al. Flow void of cerebrospinal fluid in idiopathic normal pressure hydrocephalus of the elderly: can it predict outcome after shunting? Neurosurgery 1997; 40:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/48\">",
"      Hakim R, Black PM. Correlation between lumbo-ventricular perfusion and MRI-CSF flow studies in idiopathic normal pressure hydrocephalus. Surg Neurol 1998; 49:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/49\">",
"      Jack CR Jr, Petersen RC, O'Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 1992; 42:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/50\">",
"      Holodny AI, Waxman R, George AE, et al. MR differential diagnosis of normal-pressure hydrocephalus and Alzheimer disease: significance of perihippocampal fissures. AJNR Am J Neuroradiol 1998; 19:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/51\">",
"      Savolainen S, Laakso MP, Palj&auml;rvi L, et al. MR imaging of the hippocampus in normal pressure hydrocephalus: correlations with cortical Alzheimer's disease confirmed by pathologic analysis. AJNR Am J Neuroradiol 2000; 21:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/52\">",
"      Miyoshi N, Kazui H, Ogino A, et al. Association between cognitive impairment and gait disturbance in patients with idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Disord 2005; 20:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/53\">",
"      Graff-Radford NR, Godersky JC, Jones MP. Variables predicting surgical outcome in symptomatic hydrocephalus in the elderly. Neurology 1989; 39:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/54\">",
"      De Mol J. [Prognostic factors for therapeutic outcome in normal-pressure hydrocephalus. Review of the literature and personal study]. Acta Neurol Belg 1985; 85:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/55\">",
"      Stolze H, Kuhtz-Buschbeck JP, Dr&uuml;cke H, et al. Gait analysis in idiopathic normal pressure hydrocephalus--which parameters respond to the CSF tap test? Clin Neurophysiol 2000; 111:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/56\">",
"      Wikkels&ouml; C, Andersson H, Blomstrand C, et al. Normal pressure hydrocephalus. Predictive value of the cerebrospinal fluid tap-test. Acta Neurol Scand 1986; 73:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/57\">",
"      Walchenbach R, Geiger E, Thomeer RT, Vanneste JA. The value of temporary external lumbar CSF drainage in predicting the outcome of shunting on normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 2002; 72:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/58\">",
"      Kahlon B, Sundb&auml;rg G, Rehncrona S. Comparison between the lumbar infusion and CSF tap tests to predict outcome after shunt surgery in suspected normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 2002; 73:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/59\">",
"      Malm J, Kristensen B, Karlsson T, et al. The predictive value of cerebrospinal fluid dynamic tests in patients with th idiopathic adult hydrocephalus syndrome. Arch Neurol 1995; 52:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/60\">",
"      Lenfeldt N, Hansson W, Larsson A, et al. Three-day CSF drainage barely reduces ventricular size in normal pressure hydrocephalus. Neurology 2012; 79:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/61\">",
"      Chen IH, Huang CI, Liu HC, Chen KK. Effectiveness of shunting in patients with normal pressure hydrocephalus predicted by temporary, controlled-resistance, continuous lumbar drainage: a pilot study. J Neurol Neurosurg Psychiatry 1994; 57:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/62\">",
"      Haan J, Thomeer RT. Predictive value of temporary external lumbar drainage in normal pressure hydrocephalus. Neurosurgery 1988; 22:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/63\">",
"      Duinkerke A, Williams MA, Rigamonti D, Hillis AE. Cognitive recovery in idiopathic normal pressure hydrocephalus after shunt. Cogn Behav Neurol 2004; 17:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/64\">",
"      Krauss JK, Regel JP. The predictive value of ventricular CSF removal in normal pressure hydrocephalus. Neurol Res 1997; 19:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/65\">",
"      Symon L, Dorsch NW. Use of long-term intracranial pressure measurement to assess hydrocephalic patients prior to shunt surgery. J Neurosurg 1975; 42:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/66\">",
"      Crockard HA, Hanlon K, Duda EE, Mullan JF. Hydrocephalus as a cause of dementia: evaluation by computerised tomography and intracranial pressure monitoring. J Neurol Neurosurg Psychiatry 1977; 40:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/67\">",
"      Stephensen H, Andersson N, Eklund A, et al. Objective B wave analysis in 55 patients with non-communicating and communicating hydrocephalus. J Neurol Neurosurg Psychiatry 2005; 76:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/68\">",
"      Krauss JK, Droste DW, Bohus M, et al. The relation of intracranial pressure B-waves to different sleep stages in patients with suspected normal pressure hydrocephalus. Acta Neurochir (Wien) 1995; 136:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/69\">",
"      Katzman R, Hussey F. A simple constant-infusion manometric test for measurement of CSF absorption. I. Rationale and method. Neurology 1970; 20:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/70\">",
"      Boon AJ, Tans JT, Delwel EJ, et al. Dutch normal-pressure hydrocephalus study: prediction of outcome after shunting by resistance to outflow of cerebrospinal fluid. J Neurosurg 1997; 87:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/71\">",
"      Meier U, Bartels P. The importance of the intrathecal infusion test in the diagnostic of normal-pressure hydrocephalus. Eur Neurol 2001; 46:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/72\">",
"      Malm J, Jacobsson J, Birgander R, Eklund A. Reference values for CSF outflow resistance and intracranial pressure in healthy elderly. Neurology 2011; 76:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/73\">",
"      Malm J, Lundkvist B, Eklund A, et al. CSF outflow resistance as predictor of shunt function. A long-term study. Acta Neurol Scand 2004; 110:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/74\">",
"      Vanneste J, Augustijn P, Dirven C, et al. Shunting normal-pressure hydrocephalus: do the benefits outweigh the risks? A multicenter study and literature review. Neurology 1992; 42:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/75\">",
"      Lins H, Wichart I, Bancher C, et al. Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. J Neural Transm 2004; 111:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/76\">",
"      Kudo T, Mima T, Hashimoto R, et al. Tau protein is a potential biological marker for normal pressure hydrocephalus. Psychiatry Clin Neurosci 2000; 54:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/77\">",
"      Tullberg M, Rosengren L, Blomsterwall E, et al. CSF neurofilament and glial fibrillary acidic protein in normal pressure hydrocephalus. Neurology 1998; 50:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/78\">",
"      Tullberg M, M&aring;nsson JE, Fredman P, et al. CSF sulfatide distinguishes between normal pressure hydrocephalus and subcortical arteriosclerotic encephalopathy. J Neurol Neurosurg Psychiatry 2000; 69:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/79\">",
"      Dixon GR, Friedman JA, Luetmer PH, et al. Use of cerebrospinal fluid flow rates measured by phase-contrast MR to predict outcome of ventriculoperitoneal shunting for idiopathic normal-pressure hydrocephalus. Mayo Clin Proc 2002; 77:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/80\">",
"      Egeler-Peerdeman SM, Barkhof F, Walchenbach R, Valk J. Cine phase-contrast MR imaging in normal pressure hydrocephalus patients: relation to surgical outcome. Acta Neurochir Suppl 1998; 71:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/81\">",
"      del Mar Matar&iacute;n M, Pueyo R, Poca MA, et al. Post-surgical changes in brain metabolism detected by magnetic resonance spectroscopy in normal pressure hydrocephalus: results of a pilot study. J Neurol Neurosurg Psychiatry 2007; 78:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/82\">",
"      Kristensen B, Malm J, Fagerland M, et al. Regional cerebral blood flow, white matter abnormalities, and cerebrospinal fluid hydrodynamics in patients with idiopathic adult hydrocephalus syndrome. J Neurol Neurosurg Psychiatry 1996; 60:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/83\">",
"      Owler BK, Pickard JD. Normal pressure hydrocephalus and cerebral blood flow: a review. Acta Neurol Scand 2001; 104:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/84\">",
"      Tedeschi E, Hasselbalch SG, Waldemar G, et al. Heterogeneous cerebral glucose metabolism in normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 1995; 59:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/85\">",
"      Pujari S, Kharkar S, Metellus P, et al. Normal pressure hydrocephalus: long-term outcome after shunt surgery. J Neurol Neurosurg Psychiatry 2008; 79:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/86\">",
"      Sand T, Bovim G, Grimse R, et al. Idiopathic normal pressure hydrocephalus: the CSF tap-test may predict the clinical response to shunting. Acta Neurol Scand 1994; 89:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/87\">",
"      Gustafson L, Hagberg B. Recovery in hydrocephalic dementia after shunt operation. J Neurol Neurosurg Psychiatry 1978; 41:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/88\">",
"      Raftopoulos C, Deleval J, Chaskis C, et al. Cognitive recovery in idiopathic normal pressure hydrocephalus: a prospective study. Neurosurgery 1994; 35:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/89\">",
"      Fisher CM. The clinical picture in occult hydrocephalus. Clin Neurosurg 1977; 24:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/90\">",
"      Hughes CP, Siegel BA, Coxe WS, et al. Adult idiopathic communicating hydrocephalus with and without shunting. J Neurol Neurosurg Psychiatry 1978; 41:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/91\">",
"      Czosnyka Z, Czosnyka M, Richards HK, Pickard JD. Laboratory testing of hydrocephalus shunts -- conclusion of the U.K. Shunt evaluation programme. Acta Neurochir (Wien) 2002; 144:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/92\">",
"      Ringel F, Schramm J, Meyer B. Comparison of programmable shunt valves vs standard valves for communicating hydrocephalus of adults: a retrospective analysis of 407 patients. Surg Neurol 2005; 63:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/93\">",
"      Boon AJ, Tans JT, Delwel EJ, et al. Dutch Normal-Pressure Hydrocephalus Study: randomized comparison of low- and medium-pressure shunts. J Neurosurg 1998; 88:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/94\">",
"      Weiner HL, Constantini S, Cohen H, Wisoff JH. Current treatment of normal-pressure hydrocephalus: comparison of flow-regulated and differential-pressure shunt valves. Neurosurgery 1995; 37:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/95\">",
"      Raftopoulos C, Massager N, Bal&eacute;riaux D, et al. Prospective analysis by computed tomography and long-term outcome of 23 adult patients with chronic idiopathic hydrocephalus. Neurosurgery 1996; 38:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/96\">",
"      Malm J, Kristensen B, Stegmayr B, et al. Three-year survival and functional outcome of patients with idiopathic adult hydrocephalus syndrome. Neurology 2000; 55:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/26/14762/abstract/97\">",
"      Lundkvist B, Eklund A, Kristensen B, et al. Cerebrospinal fluid hydrodynamics after placement of a shunt with an antisiphon device: a long-term study. J Neurosurg 2001; 94:750.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5069 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-210.101.131.231-9551285854-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14762=[""].join("\n");
var outline_f14_26_14762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ventriculomegaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - White matter lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Aqueduct flow void",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neuropsychologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Confirmatory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Removal of CSF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Intracranial pressure monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - CSF infusion tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cisternography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Efficacy of shunting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Predictors of shunt efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Types of shunts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Shunt complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5069\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5069|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/2/24609\" title=\"diagnostic image 1\">",
"      MRI ventriculomegaly atrophy versus NPH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/22/4450\" title=\"diagnostic image 2\">",
"      CT NPH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/16/36098\" title=\"diagnostic image 3\">",
"      CT NPH calculation of Evans ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/47/40690\" title=\"diagnostic image 4\">",
"      MRI NPH cerebral aqueduct flow void",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5069|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/61/39899\" title=\"table 1\">",
"      Predictors shunt outcome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4424?source=related_link\">",
"      Approach to the patient with chronic meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=related_link\">",
"      Clinical features and diagnosis of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=related_link\">",
"      Clinical manifestations and diagnosis of Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=related_link\">",
"      Infections of central nervous system shunts and other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15946?source=related_link\">",
"      Parkinson disease dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_26_14763="Diff dx of anaphylaxis in pregnancy";
var content_f14_26_14763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders that may mimic features of anaphylaxis during or after labor and delivery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Hypotension due to anesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension due to hemorrhage (eg, placenta previa, abruption, postpartum hemorrhage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizure or laryngeal edema associated with preeclampsia/eclampsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute pulmonary edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amniotic fluid embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decompensation of underlying cardiovascular disorder [eg, cardiomyopathy, myocarditis, acute coronary syndrome, valvular disease (eg, mitral stenosis), tetralogy of Fallot, primary pulmonary hypertension, aortic dissection, Eisenmenger syndrome, Marfan syndrome, coarctation of the aorta]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral vascular accident",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septic shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngopathia gravidarum",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14763=[""].join("\n");
var outline_f14_26_14763=null;
var title_f14_26_14764="Dx of PVE by echocardiography";
var content_f14_26_14764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Transthoracic and transesophageal echocardiography in the diagnosis of prosthetic valve endocarditis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Prosthesis type and position (number studied)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Number of valves (%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Transthoracic",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Transesophageal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Non-diagnostic",
"       </td>",
"       <td class=\"subtitle3\">",
"        Diagnostic",
"       </td>",
"       <td class=\"subtitle3\">",
"        Non-diagnostic",
"       </td>",
"       <td class=\"subtitle3\">",
"        Diagnostic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Aortic position (34)",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        18 (53)",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        29 (85)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bioprosthesis (12)",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6 (50)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        11 (92)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mechanical valve (22)",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12 (55)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        18 (82)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Mitral position (37)",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        5 (14)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        33 (89)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bioprosthesis (10)",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        2 (25)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        8 (80)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mechanical valve (27)",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        3 (11)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        25 (93)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Patients had pathoanatomic or clinically confirmed (Von Reyn criteria) PVE.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Karchmer, AW. In: Principles and Practice of Infectious Diseases, 5th ed, Mandell, GL, et al (Eds), Churchill Livingstone, Philadelphia 1999. p. 907.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14764=[""].join("\n");
var outline_f14_26_14764=null;
var title_f14_26_14765="ICD versus drugs CASH";
var content_f14_26_14765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    The implantable cardioverter-defibrillator reduces total mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 226px; background-image: url(data:image/gif;base64,R0lGODlhyAHiAOYAAP///wAAAP8AAAAzmaqqqnd3d+7u7oiIiFVVVTMzMxEREczMzCIiIt3d3aCz2fDz+URERODm85mZmYigz2ZmZru7u2CAvyBNphFBoP/w8P+goMzW61BzudDZ7HeSyZCm0//g4LDA3yJOpzNcrf9gYP9VVe7x+EBms4CZzP+IiP/Q0P8wMP+qqkRptFV3uzBZrP9ERN3k8f93d/+AgGaFwsDN5qq73RBAn3CNxpmt1v/d3f/MzP8zM/9QUP+Zmf8QEP9mZv/u7v8iIrvJ5B8sha8PL18fXw8AAM9ZbE8jae9DSX8ZTO8DCcC81v+7u48WQh8AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADIAeIAAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+QAEAELggbnARANggUBAQwE5fb3+JoE8uiCCAEEFgRIAOBAgAIAGCgwkK+hw4eL/qUDoCAAw4oG/tXTCLGjR4cSARgIoEAQxgT9OD7K8LGly2ghKVqUmREgAJWF+OkMcEQACRAvgwo1FlNjhYEFDxpQyPARlAFGmgydSlXXPn4IRLJzB08evUgBIiy58cJB1bNoqQUAIACAgxc3/1B0SEu3LrIAGQRoEFTDwgCzdgML7rVWxQ8Sgxz8Hcy4Ma21ADKsWMHS7YAIjjNrVgVZEIkfKgRhBvBgs+nTnzoL0iCgdWsmAz6gnk27kmpBlQchIcKhdO3fwBPdPqRBCYcLcwnlDs789HBDeQU8GZCkiGufQC0tb87d4fNEEVBcuIAiAggS19OrX+86e/f3+L4vCsFhAO5LJBDD319OPqTRlICg3nb8FXiNf44MsFgly/Wwl4EQHpiJYoBhokEPkRAY4Ya8IPgIhZlEx96IM3BoImGbKPaCBR/UgIoKk4Wm3Ik0xuLhfzV8YMEL9gkywAkfJAfKDOu5V+ORqdyIyf8DIVgwngUh+EaIlAwWkh+SWKKi5CYdfHCCggoK8sAAKFCJiYBGZkmbAQS02eZENs4SwQkXhMDJlYWkqWZjV+lEgSxbmhLCBScAeImA6z24p2MEMFBAAQgocA6crgRqygMoDGCBoVUWwpqiiw52AEEiBSCBTbBYekoEfm36yaehMmbQAQTEc2o9qerC6gC+mXkJrLEGZkBF8iRwFKWtqKpKr7FxAmywdRlwQAEHMNSUJAuw8xUA8cyD6yPKttLBBb1t8uwkGkILTq2PFvAOJQyg0wBJSSHEFCThtvLAcUJaOOK/6cmorjh9yvOtJP9AYNCfHOHUSL6ufNCsJnpCMsP/CgOPEw+tbV6LLT8MSAAASuk4zAjEroxbLiwrlJgxOKd6XIlCABBQUQMNo0rITjwXsy9ysKig3svbLKAAAu2+O4kCCrwTbwMGFbDUQvgeI7GvqizXFtHZFKyzJASgNBCu3W4LLjJSgglkv6lszfU1bLpJgMyVOsOkkxdAibUoAK/3djEEHNBAu48qnWs0XX6pS9/X/V1LAQl4ffArKAszAKE4oFAD24snkq7jojRQQdxu0p2sNh3UgAIOdA7AgQN7zwKwwKCfYjqg4DzgQH3FXFx7KjYjUIEtlT/zY5C/tCxIxb93UkG881Q7S/F2N/lklLsI7RqozYNSQbeT191Q/+Kuw55LZc9+3v0k0rKjwPC4Q6Q777ywdt1P62dylcK3s0K9Nq6zkyNiBwr3nGdE+YNEBQ6ArPi5JDzjKQ8iwKQgzqFCQ25LoCICNzjCGY5yU6EPBcNkiA9cgICrYFwGmwc5yU1PMxzggDBW+DvRka5jL8zMAy4gG2DQsHn9O1xmOkBCAIzwiLL4F+iCB7/HmAaFhuCU7ED3PK9Iz4HwicCCapGev33PYDnkj2KOCKYkcq198nhfGPkjRUOUr42k6KK69ndFLCJpfpqCYyl+uKcFNjBOodqVq1TBRzVVwFi3+F9zBKlHUAxtUQIJHyChtSsohqKQNGpAApBWuDVCK/9tFrDgJVVISkwyxoWVkIDYEMItr0hSEYosUHhucAIBzvAbJXBNCQQBBNf4AAC5dI0MNnHDuVViH1kZRNQSQrWzOU534zGfD0sJDRkIIAWCgME1AaADGAQhlywAQAoEAANNdDBplThHvBQgspy9EhGx3FAIThCXRhbDlMWwJjZ1IAAhFAKcguCBAJygv528kxEYaQDTRpaSr51sfR3wyzPwSQx9AoAFAtglIQAKTAGEExOko0ACgriIpzF0Ae40BM92osFBkJGCwSjlI3Nh0R30858eDagAdtCJfTRREhtTKAPqNTWS5qSlkHhpGX2koBfgAHucsOQkKOoKiwJAm/v/9CZAx1nOTJwTJQdlxD/aMZGyhVWlSP0Ek3DAI5gyVakufekgOUFVVgQzo7z0ZUddg0196IRUdkzrLirZibpm44a1iKdgR+Gbl76OSvZki9/AMTioRc6Ji00GHuNaoUcYNhoHUIBA6OXJzDIDRJD4LDQgdyqDnPUUijWtLFDrCJna9rak7MQBGPCPeb3WFLGVbSzG6FYjKrVH3VBoO071R/8JNxqRnaA3amUACRwAs88dB3K5E9zsDmO7zemud4MBXvBsRrzj/cVL4wqmziqDXZ0MbHobQttkoHKS84VIfY+xsdKVNr/03eIgomuLmCUSwB9RzGgo6N5eGI2T7vov/4LzIcX9iiYX9xXihINC3DJqscGyKKZRYbvhqbTRwrNYAAE+qOESo6XDRYQFBfhxXQm72MSEKC8rDIK0Sdn4xmdB7nF13AnIqcOh4gMy0UJLq3g0dxXoVTJEiKwJA4gtAH/6sZQzQ+UqT0tkmDgKqswKli3/psu1aIBCbLLMeznTzLNB8zEFR7gIV2KTKTXZIqIMZ3zImRItNGg6CcIRkt0EybDsc5xBYUO5GXMSo9UJAVKak5XyQ9GoQSIn9mEtREeCI1EratUwHSqRDiQBYMWESsg8alLv6crygAB2XW3IkRpgxFqi9aIO+VMt63pDkTzwr4cyAQyYwBWahDCLT/83bGuYAAMDaEEjPDCACSxCBC4AwAYUZG0AiGAAHkAEtI9dUEn7utnKmACYYpAJGwzABtpWkAgAoG5wi3sA5Aapo3FdCj6j+xUjGEDAw22CAWCgBQMQwQS+nW11WzsH0B5AtgfhgnnHG9oLh3a4N4DwaMfABWAKtyZUvOwk/xsa2xZBygFQcAzQewA08PYAYuDwbY/g5SJ/drdtDnIMqDvcIjB2DmAOgHFvYsbyqLF8T74MGozQBi3HOQACvgGH/xwA7r75y9kd7xFsmwY/3zYFb270TPC4AD5eOtOTAe0NvLwFUb861WsucKl7W9qCsPkgrh50rgsC2n6/hJFL9dv/fq/9GerW+rMHsG2Xy53xDgcAxBUUcwAM4d2D0Lsgrs5xMDVcQSK/BJNr1Q+1H34cNLA4LKzMjyyb/vThwEDoV//lxMKeQ1ArAJjPfXvgKFcersdv7/dTAAXQasa9Nvnw4aPKIxeeFP5e/kuM1q6D2BmE0t+P18DY4uw3p5g47L73m0Ny24//PUgPgNKFf37gnD3t7G9/bQY/kuePIvryd8jonVwJo8X6Xaz2Zvn3G6wHfJZwANe1D7LWZs3kCPg3gPkgLbqnCadCaDahZ4kGgb/Ba5tgM+p3Uof2fA+ogeUQbJmAdMlEaTtjafJAgrWRbOhECWPFSkTlZg7ogrSR/2GfthPpEIA3iIOoIWK8B4RpkREJIDXEQ4SmwQ4BkEyzpoSMMRIUQAAzxm/ABYWZUX9sYhFWCH1Y6BgjwTP2Jwoj+IWHtVJjGAplaIbYcGtueGtPyIa1s4ZyCBx0WIe1cYd4OBt6uIfO4YdzCIig04eCmBmEWIiNcYiIOBiKuIiB0YiOWBeQGIlpMYmUeBaWeIlUkYmaOBSc2Ine4IMPA4rvwYBW+ImkqA0qOIqp2ByGhoHC0YrNsYqCwIK2eIu4mIu6uIu82Iu++IvAGIzCOIzEWIzGeIzIeIu+EGo2yIpX+IwklmvQGI2GR43V2Aui+FDWeH9J0o3T+I1kKI3g+P8M0edv+HeO23iNXpiO4agW4riO7NiO6jiOoFCO7xgN9kiPauiN89iP+xiP9VgN+eiP8qiPnvCA5niP3OiOAHmQ/GiQnYCQDemQE6kMAwmPEEmRBFmQC5mRnICKmXCRHemRH1mRGomRKDmSsriSLNmSLvmSMBmTMjmTNFmTvyYBxLJ+oXAUThgKY/WBo7AONHYK5wBYnxCG/JCGkmAA6deFkOA1NAgKBiEPPSmVFcFO0CAQFqiUjyA2VfkJCPAOKJF8nZAtDDGWpVB8SBEKYeiUlpAAooUK8cKVjXAqWTFjOtlT7QCCzrBMyzQKAvGVoZBqpgCXbhkJOFmBooCUB1H/CkcBPRBwmJDAY4BJEpDSNKKwMUmRl8mgmX8pCoFpCupkCmMVfN5jKlpZmKZCCsuEl0FZEU+2CT+JAJLZCJQ5K8/gl41ZmYJZlusUm57wD7sHCj9ZLGkJlKJwKn+CTKMQD6b5Cbh5Ds/ZCdqyms6QmudAl44QmqBZLMCpCQeQZecwnN1plJ4waYJgaK/JAEyJnJ8gEA0YCguTFNPpCQvAAObJDDiZdKQAa9/ZfzvRm5twn0NpCqkZCmrmFeQZCo3Cn6JwDlEpCulXn5xALBRQmzaZoRq6oRzaoR76oSAaoiI6oiRaoiZ6oiiaoiq6oohgEKQSLwvKonSBEgi4lzI6dhhHwTSYmS3/JxNUWTOnlgALcGX/eaPdgHQ1xhTKSQjxUgF9gmrWaaQNMS8lAQCRZpzdYjDMCQCnUiwYKqXRMBJVykxKYxCyphFbOggoEaNgCg5iOgg8SpWspwBgtaXEgmVtmqd6uqd82qd++qeAGqiCOqiEGggAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the CASH study of 349 patients followed for 57 months, total mortality is lower with the implantable cardioverter-defibrillation (ICD) compared to therapy with amiodarone (Amio) or metoprolol (Met) (36.4 versus 44.9 percent); however, the difference was not significant (p = 0.08). When Amio and Met were considered separately, there was also no significant difference.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kuck, KH, Cappato, R, Siebels, J, Ruppel, R, for the CASH Investigators. Circulation 2000; 102:748.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14765=[""].join("\n");
var outline_f14_26_14765=null;
var title_f14_26_14766="Properties beta blockers";
var content_f14_26_14766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Beta blocker properties",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alpha blockade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Beta-1 selectivity",
"       </td>",
"       <td class=\"subtitle1\">",
"        ISA",
"       </td>",
"       <td class=\"subtitle1\">",
"        MSA",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lipophilicity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual dose*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Half life, hours&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Elimination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acebutolol",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        100 to 400 mg BID",
"       </td>",
"       <td>",
"        3&nbsp;to 4",
"       </td>",
"       <td>",
"        <p>",
"         Hepatic (1&deg;)",
"        </p>",
"        <p>",
"         Renal (2&deg;)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atenolol",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        50 to 200 mg once daily",
"       </td>",
"       <td>",
"        6&nbsp;to 9",
"       </td>",
"       <td>",
"        Renal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Betaxolol",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        10 to 20 mg once daily",
"       </td>",
"       <td>",
"        14&nbsp;to 22",
"       </td>",
"       <td>",
"        <p>",
"         Hepatic (1&deg;)",
"        </p>",
"        <p>",
"         Renal (2&deg;)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bisoprolol",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        2.5 to 20 mg once daily",
"       </td>",
"       <td>",
"        9&nbsp;to 12",
"       </td>",
"       <td>",
"        Renal and hepatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carteolol",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        2.5 to 5 mg once daily",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Renal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carvedilol",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        3.125 to 25 mg BID",
"       </td>",
"       <td>",
"        7&nbsp;to 10",
"       </td>",
"       <td>",
"        <p>",
"         Biliary (1&deg;)",
"        </p>",
"        <p>",
"         Hepatic (2&deg;)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esmolol",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        IV only 500 mcg/kg over one minute then 50 mcg/kg/min titrated&Delta;",
"       </td>",
"       <td>",
"        9 min",
"       </td>",
"       <td>",
"        Blood esterases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Labetalol",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        <p>",
"         IV 20 mg&Delta;",
"        </p>",
"        <p>",
"         Orally&nbsp;100-400 mg BID/TID",
"        </p>",
"       </td>",
"       <td>",
"        3&nbsp;to 4",
"       </td>",
"       <td>",
"        Hepatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metoprolol",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        <p>",
"         IV 1.25 to 5 mg&Delta;",
"        </p>",
"        <p>",
"         Orally&nbsp;25 to 100 mg BID/TID",
"        </p>",
"        <p>",
"         XL 50 to 400 mg once daily",
"        </p>",
"       </td>",
"       <td>",
"        3&nbsp;to 7",
"       </td>",
"       <td>",
"        Hepatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nadolol",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        40 to 160 mg once daily",
"       </td>",
"       <td>",
"        20&nbsp;to 24",
"       </td>",
"       <td>",
"        Renal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nebivolol",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        5 to 40 mg once daily",
"       </td>",
"       <td>",
"        <p>",
"         10&nbsp;to 12",
"        </p>",
"        <p>",
"         (19&nbsp;to 32 poor metabolizers)",
"        </p>",
"       </td>",
"       <td>",
"        Hepatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxprenolol&loz;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        40 to 80 mg TID",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        Hepatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penbutolol",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        10 to 40 mg once daily",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Hepatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pindolol",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        5 to 30 mg BID",
"       </td>",
"       <td>",
"        3&nbsp;to 4",
"       </td>",
"       <td>",
"        <p>",
"         Hepatic (1&deg;)",
"        </p>",
"        <p>",
"         Renal (2&deg;)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propranolol",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        <p>",
"         IV 1 to 5 mg&Delta;",
"        </p>",
"        <p>",
"         Orally&nbsp;10 to 80 mg BID/TID or four times daily",
"        </p>",
"       </td>",
"       <td>",
"        3&nbsp;to 4",
"       </td>",
"       <td>",
"        Hepatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sotalol&sect;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        80 to 160 mg BID",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        Renal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Timolol",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        10 to 30 mg BID",
"       </td>",
"       <td>",
"        4&nbsp;to 5",
"       </td>",
"       <td>",
"        <p>",
"         Hepatic (1&deg;)",
"        </p>",
"        <p>",
"         Renal (2&deg;)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ISA: intrinsic sympathomimetic activity; MSA: membrane stabilizing activity; BID: twice daily; TID: three times daily.",
"     <br>",
"      * Range of usual, oral, anti-hypertensive dose, unless \"IV\" noted.",
"      <br>",
"       &bull; Duration of hypotensive effect, in general, is longer than may be predicted by serum half-life.",
"       <br>",
"        &Delta; Usual initial IV dose. Subsequent dosing generally needed. See specific drug information topic for detail.",
"        <br>",
"         &loz; Not available in US.",
"         <br>",
"          &sect; Sotalol has independent class III antiarrhythmic activity.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Includes data from: Frishman WH, Alwarshetty M. &beta;-Adrenergic blockers in systemic hypertension pharmacokinetic considerations related to current guidelines; Clin Pharmacokinet 2002;41:505-16.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14766=[""].join("\n");
var outline_f14_26_14766=null;
var title_f14_26_14767="Trans fx medial sesamoid B";
var content_f14_26_14767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Transverse fracture of the medial sesamoid (white arrow)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_26_14767=[""].join("\n");
var outline_f14_26_14767=null;
